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ABSTRACT 
Cancer has become number one cause of death. Conventional treatment includes 
surgery, chemotherapy, radiation therapy, or combination. The combinatorial therapy 
in one system is highly efficient and economical. Herein, two drug delivery systems 
with chemo and photothermal therapy are developed in order to enhance the 
therapeutic efficacy in A549 human lung cancer cells. The first one is hollow copper 
sulfide nanoparticle carrying doxorubicin (PEG-HCuSNPs-DOX). The second one is 
mesoporous silica coated CuS nanoparticles (CuS NPs) loaded with doxorubicin 
(DOX) (PEG-CuS@MSNs-DOX).  
Both nano-drug delivery systems are pH sensitive, laser responsive, and 
photothermal convertible. CuS NPs are the photothermal sensitizers in both drug 
delivery systems. However the drug loading efficiency is much higher in the 
PEG-CuS@MSNs-DOX, whereas its drug release rate is much slower. In addition, the 
anti-cancer efficacy of PEG-HCuSNPs-DOX is higher than that of 
PEG-CuS@MSNs-DOX.  
Five chapters are prepared in this thesis. Each chapter includes an independent 
manuscript and separate abstract. Chapter 2 serves as preparation experiment for 
chapter 3. Chapter 4 is a review that expands the application of CuS NPs to 
transdermal delivery. Chapter 5 is a mini review on the in vivo application of CuS NPs  
1. Cancer Photothermal Chemo Therapy Using Hollow Copper Sulfide 
Doxorubicin	  Nanoparticles  
 
  
The design and synthesis of the multifunctional nanoparticles responsive to 
external stimuli provides potential applications in biomedical fields such as controlled 
drug delivery. Here, near infrared (NIR) laser-controlled fast and effective tumor cell 
killing is achieved based on the pH sensitive and NIR light responsive hollow copper 
sulfide nanoparticles chelated with doxorubicin molecules (HCuSNPs-DOX). Laser 
exposure at 900 nm and acidic environment facilitate the release of DOX from 
HCuSNPs-DOX. Spontaneously, the released DOX forms DOX/Cu2+ complex and 
generates cell-killing reactive oxygen species. Laser exposure to HCuSNPs-DOX also 
disrupts the integrity of the cell membrane instantly. The IC50 of HCuSNPs-DOX with 
and without laser treatment was 4.0 and 7.6 µg/mL CuS, respectively. The approach 
developed here offers compelling chances for quick-responsive anticancer therapy.  
2. Facile Direct Dry Grinding Synthesis of Monodisperse Lipophilic CuS 
Nanoparticles 
Copper sulfide with near-infrared light absorption property is recently attracting 
broad interest as a photothermal carrier for smart cancer therapy. Lipophilic copper 
sulfide nanoparticle is preferred for high performance biomedical applications due to 
the high affinity with tissues. But it requires complex multi-step synthetic process 
under severe condition. Here, synthesis of hydrophobic copper sulfide possessing 
surface plasmon resonance was retained by direct dry grinding of copper(II) 
acetylacetonate with sulfur under ambient environment. The formed CuS 
nanoparticles were in uniform size of ~10 nm, and they were monodispersed in pure 
chloroform. Each covellite CuS nanocrystal surface was modified with oleylamine 
through hydrogen bonding between sulfur atoms and amine groups of oleylamine. 
  
While those oleylamine capped CuS nanoparticles showed uniform morphological 
features, they demonstrated near-infrared light absorption for photothermal 
applications. The facile and mild synthetic methodology described here opened a 
powerful pathway for the design and preparation of photothermal lipophilic copper 
sulfide nanomaterials for smart cancer therapy. 
3. Multifunctional Mesoporous Silica-Coated CuS Nanoparticles for Cancer 
Therapy: Synthesis, Characterization and in vitro Evaluation 
Chemo therapeutic drug-caused side effects are commonly seen in clinical practice 
due to nonspecific toxicity and low therapeutic efficiency. Herein, we reported a 
cancer chemo-photothermal multifunctional drug delivery system. Polyethylene glycol 
decorated mesoporous silica nanoparticles entrapping CuS nanoparticles 
(PEG-CuS@MSNs) were successfully synthesized and characterized for the drug 
delivery application. Doxorubicin (DOX)-loaded PEG-CuS@MSNs showed laser 
stimulated and pH-responsive properties. In vitro cell experiments demonstrated that 
DOX-loaded PEG-CuS@MSNs combining laser exposure achieved the highest rate of 
death of A549 cells, in comparison to that of PEG-CuS@MSNs-DOX chemotherapy 
alone. These findings provided a promising drug delivery system for cancer 
combinatorial therapy, which could significantly reduce drug dose and improve patient 
compliance. 
4. Laser ablation-enhanced transdermal drug delivery 
Transdermal delivery offers an excellent route for drug and vaccine administration. 
Nonetheless, it presents a critical challenge due to the skin’s lipid-rich outer stratum 
  
corneum layer. Laser ablation perforates epidermis through selective photothermolysis, 
making skin more permeable to hydrophilic and macromolecular drugs such as 
peptides, proteins, and genes. This review summarizes recent applications to laser 
ablation-enhanced transdermal delivery. Needle- and pain-free transcutaneous drug 
delivery via laser ablation provides an alternative approach to achieve local or 
systemic therapeutics.  
5. Cancer Photothermal Therapy and CuS Nanoparticles 
This manuscript is being prepared according to the format of Lasers in Medical 
Science as a review article.  
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PREFACE 
  This dissertation is written based on the University of Rhode Island “Guidelines for 
the Format of Theses and Dissertations” standards for Manuscript format. This 
dissertation is composed of four manuscripts that have been combined to satisfy the 
requirements of the department of Biomedical and Pharmaceutical Sciences, College 
of Pharmacy, University of Rhode Island. 
Manuscript 1: Cancer Photothermal Chemo Therapy Using Hollow Copper 
Sulfide Doxorubicin Nanoparticles 
  This manuscript is being prepared for submission to ACS nano. 
Manuscript 2: Facile Direct Dry Grinding Synthesis of Monodisperse Lipophilic 
CuS Nanoparticles 
  This manuscript is being prepared for submission to Materials Chemistry and 
Physics. 
Manuscript 3: Multifunctional Mesoporous Silica-Coated CuS Nanoparticles for 
Cancer Therapy: Synthesis, Characterization and in vitro Evaluation 
  This manuscript is being prepared for submission to Journal of American Chemical 
Society. 
Manuscript 4: Yajuan Li, Liangran Guo, Wei Lu. Laser ablation-enhanced 
transdermal drug delivery. Photonics and Lasers in Medicine. 2012, 2(4): 315–
322 (review) 
  This manuscript has been published as a review paper. 
Manuscript 5: Cancer Photothermal Therapy and CuS Nanoparticles 
This manuscript is being prepared for submission to Lasers in Medical Science.
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ABSTRACT: The design and synthesis of the multifunctional nanoparticles 
responsive to external stimuli provides potential applications in biomedical fields such 
as controlled drug delivery. Here, near infrared (NIR) laser-controlled fast and 
effective tumor cell killing is achieved through the pH sensitive and NIR light 
responsive hollow copper sulfide nanoparticles chelated with doxorubicin molecules 
(PEG-HCuSNPs-DOX). Laser exposure at 900 nm and acidic environment facilitate 
the release of DOX from PEG-HCuSNPs-DOX. Spontaneously, the released DOX 
forms DOX/Cu2+ complex and generates cell-killing reactive oxygen species. Laser 
exposure to PEG-HCuSNPs-DOX also disrupts the integrity of the cell membrane 
instantaneously. The IC50 of PEG-HCuSNPs-DOX with and without laser treatment 
was 4.0 and 7.6 µg/mL CuS, respectively. The approach developed here offers 
compelling chances for controlled anticancer therapy.  
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INTRODUCTION 
Cancer has nowadays become one of the most deadly diseases in the world. As 
reported in 2013, the 5-year global cancer prevalence is estimated to be 28.8 million in 
a population of 49.2 million in 2008.1 Doxorubicin (DOX), as an effective tumor 
chemotherapeutic drug, causes life-threatening dosage-dependent cardiac toxicity.2 
Efforts in drug delivery have been made to enhance efficacy, reduce dosage, and 
minimize side effects. The marketed DOX liposome injection Doxil®3 and various 
multifunctional nanoparticles with assorted composites were developed as reviewed 
by Prados4 and Hanušová.5 
Copper sulfide nanoparticles are a new class of photothermal sensitizer providing 
an affordable counterpart for gold nanoparticles. The light absorption of the former is 
affected by the surrounding environment.6, 7 Originating from the d–d* transition of 
Cu2+ ions in copper sulfide, such nanoparticle exhibits stable light absorption towards 
near-infrared (NIR) light irradiation (650–900 nm),8 which can penetrate through 
normal tissues with minimal thermal injury.9 Instantaneously upon NIR light 
absorption, copper sulfide nanoparticles generated heat and photothermally ablated 
tumor in vivo after intratumor10, 11 or intravenous injection.12 In our previous work, 
hollow copper sulfide nanoparticles (HCuSNPs) were applied for photothermal 
ablation-enhanced transdermal drug delivery.13 Once the HCuSNPs enriched on skin 
surface was irradiated by nanosecond-pulsed NIR laser, high heat energy was 
generated within very short time, which disrupted stratum corneum of the local skin 
and facilitated permeation of human growth hormone. Recently, copper sulfide 
nanoparticles were coated with DOX conjugated gelatin, achieving enzyme-responsive 
 4 
 
drug release simultaneous photoacoustic imaging and photothermal therapy upon NIR 
laser.14 Unfortunately, the resultant nanocomposites required relatively long time and 
high power of NIR laser irradiation (> 5 min, 6 W/cm2) to achieve desired therapeutic 
efficacy, which set barrier for practical applications in controlled cancer therapy.14 
In this work, nanosecond-pulsed NIR laser controlled anticancer therapy is 
achieved by PEG-HCuSNPs loaded with DOX. The shell of PEG-HCuSNP consists of 
many 8-nm large polyethylene glycol (PEG) modified copper sulfide nanocrystals. 
DOX molecules are loaded on the PEG-HCuSNPs through chelation. The pH-sensitive 
nanocomposites tend to release a proportion of DOX after reaching the acidic tumor 
site or lysosomes in the cells. NIR laser irradiation of the PEG-HCuSNPs-DOX 
produces instantaneous heat and allows most of the DOX molecules to be released into 
surrounding environment. The chemotherapy drug molecules further interact with 
Cu2+ ions and generate reactive oxygen species (ROS), resulting in fast and highly 
efficient pH-sensitive, chemo and photothermal cell killing effect. The current work 
provides a facile and effective way for smart controlled antitumor therapy.  
RESULTS AND DISCUSSION 
The preparation of PEG-HCuSNPs-DOX was carried out as illustrated in Scheme 
1. 
 5 
 
 
Scheme 1. Schematic illustration of the preparation procedure of the 
PEG-HCuSNPs-DOX and NIR laser controlled drug release process.  
The transmission electron microscopy (TEM) image of the as-prepared HCuSNPs 
demonstrated hollow structures with the average diameter of 75 ± 11 nm (Figure 1a). 
The shells were ~20-nm thick, and consisted of 8-12-nm large nanoparticles. After 
surface modification with thiolated PEG, a thin layer (thickness ~4 nm) was clearly 
observed on the particle surfaces, while the initial structures of HCuSNPs did not 
change (Figure 1b). Loading of DOX did not significantly change the size and 
morphology of the nanoparticles (Figure 1c). Dynamic light scattering (DLS) analysis 
revealed that the hydrodynamic particle size of the PEG-HCuSNPs-DOX was 80 ± 10 
nm, which agreed well with the TEM observations. As shown in the UV–Vis spectrum 
(Figure 1d), PEG-HCuSNPs exhibited strong absorbance peak centered at ~1050 nm, 
which was ascribed to the d–d* transition of copper sulfide.20 Similar absorbance was 
found in the UV–Vis spectrum of PEG-HCuSNPs-DOX, but with a minor red shift of 
5 nm due to the DOX chelation on HCuSNPs.15 When compared with the green 
 6 
 
aqueous dispersion of PEG-HCuSNPs, the aqueous dispersion of 
PEG-HCuSNPs-DOX was more brownish (Figure 1e). The drug loading increased 
with the increase of time (Figure 1f). The PEG-HCuSNPs and PEG-HCuSNPs-DOX 
remained stable in DI water at room temperature for at least 3 months. The DOX 
loading efficiency of the PEG-HCuSNPs-DOX was optimized ~6.0 wt.%. 
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Figure 1. TEM images of HCuSNPs (a), PEG-HCuSNPs (b), PEG-HCuSNPs-DOX 
(c), Bars, 50 nm. UV–vis spectra (d), the inset is the enlarged UV–vis spectra. 
Photograph of the dispersions (e) containing PEG-HCuSNPs (left) and 
PEG-HCuSNPs-DOX (right). Loading efficiency change over 5 days (f). Samples 
were taken at time point 0, 0.42 , 1, 2, 3 and 5 day. Data were expressed as Mean ± SD. 
n=3.  
The drug release profiles of HCuSNPs-DOX were studied in the media with 
respective pH of 7.4, 6.0 and 5.0 over a 4-h period. Without laser irradiation, the 
cumulative release of DOX was 16.6%, 23.0% and 33.9%, respectively (Figure 2). 
DOX release from PEG-HCuSNPs-DOX was pH dependent. On the other hand, NIR 
laser irradiation accelerated DOX release in various pH conditions. While the DOX 
released in 1 h was 3.8 ± 2.2% (pH 7.0), 12.6 ± 0.9% (pH 6.0), and 25.0 ± 2.7% (pH 
5.0), the released amount increased to 27.9 ± 0.9%, 37.8 ± 2.0%, and 47.7 ± 3.7% 
after the first laser irradiation (2.0 W/cm2, 15 s, 900nm). The drug release slowed 
down when the laser was switched off. The laser-triggered release was well responsive 
 8 
 
to the repeated laser irradiation. By the end of 4 h with 3 times of laser exposure, the 
cumulative release of DOX reached 48.1%, 58.7% and 75.6% at pH 7.4, 6.0 and 5.0, 
respectively. Significantly, in the pH 5.0 medium, the cumulative release of DOX with 
NIR laser treatment was 2.2 folds higher compared with that without laser irradiation. 
The dual-module release profile of PEG-HCuSNPs-DOX presented a spatiotemporal 
controlled release manner through which the drug can be specifically released at the 
tumor site either applying NIR laser or under the acidic environment of the tumor.16 
 
 
Figure 2. DOX cumulative release from PEG-HCuSNPs-DOX under different pH 
buffers containing 10% BSA. The laser irradiation was administrated at time point 1, 2 
and 3 h. (2 W/cm2, 15 s, red lines). Data were expressed as Mean ± SD. n=3. 
As reported, DOX formed water soluble complexes with Cu2+ below pH 8. 
Specifically, within pH range of 4.2 to 5.8, the drug and Cu2+ formed incomplete 2:1 
DOX/Cu2+ complex; at pH 5.8, 2:1 ratio complex formed exclusively regardless of 
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excessive copper; above 5.8, both DOX/Cu2+ complexes with ratio of 1:1 and 2:1 
existed; and at pH 7.3, only 1:1 complex was obtained.17 To test whether the 
laser-treated PEG-HCuSNPs-DOX released free drug only or both free drug and 
copper ion, or even further to form DOX/Cu2+ complex, we used the UV–vis, circular 
dichroism (CD), and fluorescence spectra to characterize free DOX, DOX/Cu2+ 
complex and the supernatant of PEG-HCuSNPs-DOX with or without NIR laser 
irradiation at pH 5 and 6. UV and CD spectra of samples at pH 7.4 were not able to be 
analysed due to the limitation of sampling quantity and the instrument sensitivity, 
however, inductively coupled plasma mass spectrometry (ICP-MS, data not shown) 
and fluorescence data clearly indicating the existence of copper and doxorubicin. At 
pH 5, the band intensity of DOX near 478 and 498 nm decrease upon the partial 
formation of DOX/Cu2+ 2:1 complex. In addition, the absorbance peak near 535 nm 
increased (Figure 3a). The released samples with or without laser treatment all showed 
similar absorbance curves to the complex rather than free DOX, indicating formation 
of the DOX/Cu2+ complex. When pH increased to 6, both 2:1 and 1:1 complex exist. 
As shown in Figure 3a, the absorbance of the DOX/Cu2+ complex at 480 nm continued 
to decrease and the broad band was centered at 506 nm. The band at 550 nm increased 
significantly. The released samples showed similar changes. 
In comparison with free DOX, the CD spectrum of DOX/Cu2+ at pH 5 and 6 
showed negative and positive bands at 490 and 550 nm respectively, which were 
typical of DOX/Cu 2:1 complexes (Figure 3b). The same trend was shown in the 
supernatant from laser treated PEG-HCuSNPs-DOX at pH 5 and 6. Combining the 
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UV results, it could be concluded that the DOX/Cu2+ 2:1 complex forms after laser 
treatment at pH 5 and 6.  
Fluorescent spectra of the DOX and Cu2+ mixture demonstrated the reduced 
fluorescent intensity at both pH 5 and 6, indicating the formation of DOX/Cu2+ 
complex, the fluorescence of which was quenched (Figure 3c). It should be noticed 
that as pH increased from 5 to 6 and 7.4, the intensity decreased, revealing that more 
free DOX were chelated by Cu2+. Addition of excess ethylenediaminetetraacetic acid 
(EDTA) with 1 h incubation at 60 ºC recovered the fluorescence intensity since EDTA 
competed for the ligation of Cu2+.18 The same trend was shown in the supernatant 
from laser treated PEG-HCuSNPs-DOX at pH 5, 6 and 7.4. In addition, the released 
amount of DOX was pH-dependent. At pH 5, the laser treated PEG-HCuSNPs-DOX 
sample showed the highest absorbance of DOX among the different buffer solution 
groups. 
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Figure 3. UV-vis (a) and CD (b) spectra of 100 µM DOX, 100 µM DOX/Cu2+, 100 
µM DOX released from PEG-HCuSNPs-DOX and 100 µM DOX released from 
HCuSNPs-DOX with laser treatment in the medium of pH 5, 6 acetic buffer solution. 
Fluorescence (c) spectra of 100 µM DOX, 100 µM DOX/Cu2+, 100 µM DOX/Cu2+ 
+EDTA and DOX released from PEG-HCuSNPs-DOX containing 100 µM DOX in 
the medium of pH 5, 6 acetic buffer solution and pH 7.4 phosphate buffer solution 
respectively. Released samples were incubated with excessive EDTA for 1 h at 60 ºC 
to recover the fluorescence of DOX. 
To ensure the successful uptake of PEG-HCuSNPs-DOX into cells, uptake and 
elimination studies were performed. The result showed that the intracellular amount of 
DOX reached plateau at 2 h following incubation with either free DOX or 
PEG-HCuSNPs-DOX (Figure 4). The uptake of DOX in PEG-HCuSNPs-DOX was 
1.23 fold as high as that of free DOX (p<0.05). There was no significant difference in 
elimination profile between PEG-HCuSNPs-DOX and free DOX following 4-h 
uptake.  
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Figure 4. Intercellular uptake and eliminate of DOX or PEG-HCuSNPs-DOX after the 
4-h uptake. Mean ± SD, n= 3. (* p < 0.05) 
 To investigate the mechanism of drug release in vitro, cell lysosome was stained with 
Lysotracker Blue to track the intracellular distribution of the drug. As shown in Figure 
5a, most of the fluorescence of DOX colocalized with that of Lysotracker, and 
achieved high intensity adjacent to the nuclei, suggesting intracellular uptake of DOX 
through the process of endocytosis of the PEG-HCuSNPs-DOX. Upon laser exposure, 
the fluorescence of DOX spread throughout the cells except nuclei, indicating 
laser-induced endolysosomal escape of the nanoparticles and drug release into 
cytoplasm (Figure 5b). This was attributed to photothermally induced disruption of 
endolysosomal membranes mediated by HCuSNPs.19 
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Figure 5. Fluorescent microscopy images of A549 cells incubated for 4 h with 
PEG-HCuSNPs-DOX (a) and PEG-HCuSNPs-DOX plus laser ( 2.0 W/cm2, 15 s) (b) 
at the end of incubation. Lysosome fluorescence (pseudo-green); DOX fluorescence 
(red); overlap (yellow). Scale bar: 50 µm. 
DOX induced the generation of reactive oxygen species (ROS), thus causing the 
oxidation of lipid, protein, and DNA in cancer cells20–25. More interestingly, transition 
metal ion has been indicated to be a critical cofactor facilitating this process.15 To 
prove that DOX/Cu2+ complex released from PEG-HCuSNPs-DOX could assist ROS 
generation and therefore induce therapeutic effects on cancer cells, ROS level was 
tested via fluorescence imaging and quantification. As shown in the fluorescent 
microscope images (Figure 6a), only weak signal of ROS species was detected from 
free DOX, PEG-HCuSNPs or PEG-HCuSNPs with NIR laser exposure. However, 
existence of ROS was clearly shown by the green fluorescence in the cases of 
PEG-HCuSNPs-DOX and DOX/Cu2+ complex with NIR laser irradiation (Figure 6a). 
The intensity of reactive oxygen species signal increased after NIR laser irradiation 
(Figure 6b), because the HCuSNPs released Cu2+ ions 13 and facilitated DOX 
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molecules to chelate with Cu2+. As comparisons, the generation of reactive oxygen 
species by hollow gold nanoparticles (HAuNPs) and DOX modified gold 
nanoparticles (HAuNPs-DOX) was studied under the identical condition. However, no 
such fluorescence was observed from either sample despite of the NIR laser irradiation 
(Figure 6b). Therefore, the cancer killing effect of PEG-HCuSNPs-DOX could be 
attributed to a combination of DOX release, photothermal effect, and copper induced 
ROS generation following NIR laser irradiation. The One-way analysis of variance 
(One-way ANOVA) results were shown in Table 1. and Table 2. 
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Figure 6. (a) Fluorescence microscopy images of A549 cells incubated for 2 h with 
DOX, DOX/Cu2+, PEG-HCuSNPs or PEG-HCuSNPs-DOX and then treated with the 
NIR laser ( 2.0 W/cm2, 15 s). The cells were sustained with fluorogenic probe 
2’,7’-dichlorodihydrofluorescin diacetate (DCFH-DA). Green fluorescence indicated 
the existence of ROS. Scale bar: 50 µm. (b) Normalized ROS intensity before and 
after treatments. (* P<0.05 when compared with free DOX. Mean ±SD, n=3). 
 
Table 1. ANOVA Result 
ROS Level 
 Sum of Squares df Mean Square F Sig. 
Between Groups 16.696 9 1.855 19.704 .000 
Within Groups 2.824 30 .094   
Total 19.521 39    
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Table 2. Multiple Comparisons 
Dependent Variable: ROS Level 
 Tukey HSD 
(I) GROUP (J) GROUP Mean 
Difference 
(I-J) 
Std. 
Error 
Sig. 95% Confidence 
Interval 
Lower 
Bound 
Upper 
Bound 
DOX 
DOX/CU2+ -1.0705* .2170 .001 -1.811 -.330 
PEG-HCuSNPS -.3350 .2170 .863 -1.075 .405 
PEG-HCuSNPs-DOX 
+ Laser 
-1.1725* .2170 .000 -1.913 -.432 
DOX + Laser -.2250 .2170 .987 -.965 .515 
DOX/CU2+ + Laser -1.3233* .2170 .000 -2.063 -.583 
PEG-HCuSNPs + 
Laser 
-.7375 .2170 .050 -1.478 .003 
PEG-HCuSNPS-DOX 
+ Laser 
-1.9825* .2170 .000 -2.723 -1.242 
HAuNP-DOX -.0270 .2170 1.000 -.767 .713 
HAuNP-DOX + Laser -.0083 .2170 1.000 -.748 .732 
DOX/CU2+ 
DOX 1.0705* .2170 .001 .330 1.811 
PEG-HCuSNPS .7355 .2170 .052 -.005 1.476 
PEG-HCuSNPs-DOX 
+ Laser 
-.1020 .2170 1.000 -.842 .638 
DOX + Laser .8455* .2170 .016 .105 1.586 
DOX/CU2+ + Laser -.2528 .2170 .972 -.993 .487 
PEG-HCuSNPs + 
Laser 
.3330 .2170 .867 -.407 1.073 
PEG-HCuSNPS-DOX 
+ Laser 
-.9120* .2170 .007 -1.652 -.172 
HAuNP-DOX 1.0435* .2170 .001 .303 1.784 
HAuNP-DOX + Laser 1.0622* .2170 .001 .322 1.802 
PEG-HCuSNPS 
DOX .3350 .2170 .863 -.405 1.075 
DOX/CU2+ -.7355 .2170 .052 -1.476 .005 
PEG-HCuSNPs-DOX 
+ Laser 
-.8375* .2170 .017 -1.578 -.097 
DOX + Laser .1100 .2170 1.000 -.630 .850 
DOX/CU2+ + Laser -.9883* .2170 .003 -1.728 -.248 
 18 
 
PEG-HCuSNPs + 
Laser 
-.4025 .2170 .697 -1.143 .338 
PEG-HCuSNPS-DOX 
+ Laser 
-1.6475* .2170 .000 -2.388 -.907 
HAuNP-DOX .3080 .2170 .911 -.432 1.048 
HAuNP-DOX + Laser .3267 .2170 .879 -.413 1.067 
PEG-HCuSNPs-DOX 
+ Laser 
DOX 1.1725* .2170 .000 .432 1.913 
DOX/CU2+ .1020 .2170 1.000 -.638 .842 
PEG-HCuSNPS .8375* .2170 .017 .097 1.578 
DOX + Laser .9475* .2170 .005 .207 1.688 
DOX/CU2+ + Laser -.1508 .2170 .999 -.891 .589 
PEG-HCuSNPs + 
Laser 
.4350 .2170 .602 -.305 1.175 
PEG-HCuSNPS-DOX 
+ Laser 
-.8100* .2170 .023 -1.550 -.070 
HAuNP-DOX 1.1455* .2170 .000 .405 1.886 
HAuNP-DOX + Laser 1.1642* .2170 .000 .424 1.904 
DOX + Laser 
DOX .2250 .2170 .987 -.515 .965 
DOX/CU2+ -.8455* .2170 .016 -1.586 -.105 
PEG-HCuSNPS -.1100 .2170 1.000 -.850 .630 
PEG-HCuSNPs-DOX 
+ Laser 
-.9475* .2170 .005 -1.688 -.207 
DOX/CU2+ + Laser -1.0983* .2170 .001 -1.838 -.358 
PEG-HCuSNPs + 
Laser 
-.5125 .2170 .382 -1.253 .228 
PEG-HCuSNPS-DOX 
+ Laser 
-1.7575* .2170 .000 -2.498 -1.017 
HAuNP-DOX .1980 .2170 .995 -.542 .938 
HAuNP-DOX + Laser .2167 .2170 .990 -.523 .957 
DOX/CU2+ + Laser 
DOX 1.3233* .2170 .000 .583 2.063 
DOX/CU2+ .2528 .2170 .972 -.487 .993 
PEG-HCuSNPS .9883* .2170 .003 .248 1.728 
PEG-HCuSNPs-DOX 
+ Laser 
.1508 .2170 .999 -.589 .891 
DOX + Laser 1.0983* .2170 .001 .358 1.838 
PEG-HCuSNPs + 
Laser 
.5858 .2170 .219 -.154 1.326 
PEG-HCuSNPS-DOX 
+ Laser 
-.6592 .2170 .113 -1.399 .081 
HAuNP-DOX 1.2963* .2170 .000 .556 2.036 
 19 
 
HAuNP-DOX + Laser 1.3150* .2170 .000 .575 2.055 
PEG-HCuSNPs + 
Laser 
DOX .7375 .2170 .051 -.003 1.478 
DOX/CU2+ -.3330 .2170 .867 -1.073 .407 
PEG-HCuSNPS .4025 .2170 .697 -.338 1.143 
PEG-HCuSNPs-DOX 
+ Laser 
-.4350 .2170 .602 -1.175 .305 
DOX + Laser .5125 .2170 .382 -.228 1.253 
DOX/CU2+ + Laser -.5858 .2170 .219 -1.326 .154 
PEG-HCuSNPS-DOX 
+ Laser 
-1.2450* .2170 .000 -1.985 -.505 
HAuNP-DOX .7105 .2170 .068 -.030 1.451 
HAuNP-DOX + Laser .7292 .2170 .056 -.011 1.469 
PEG-HCuSNPS-DOX 
+ Laser 
DOX 1.9825* .2170 .000 1.242 2.723 
DOX/CU2+ .9120* .2170 .007 .172 1.652 
PEG-HCuSNPS 1.6475* .2170 .000 .907 2.388 
PEG-HCuSNPs-DOX 
+ Laser 
.8100* .2170 .023 .070 1.550 
DOX + Laser 1.7575* .2170 .000 1.017 2.498 
DOX/CU2+ + Laser .6592 .2170 .113 -.081 1.399 
PEG-HCuSNPs + 
Laser 
1.2450* .2170 .000 .505 1.985 
HAuNP-DOX 1.9555* .2170 .000 1.215 2.696 
HAuNP-DOX + Laser 1.9742* .2170 .000 1.234 2.714 
HAuNP-DOX 
DOX .0270 .2170 1.000 -.713 .767 
DOX/CU2+ -1.0435* .2170 .001 -1.784 -.303 
PEG-HCuSNPS -.3080 .2170 .911 -1.048 .432 
PEG-HCuSNPs-DOX 
+ Laser 
-1.1455* .2170 .000 -1.886 -.405 
DOX + Laser -.1980 .2170 .995 -.938 .542 
DOX/CU2+ + Laser -1.2963* .2170 .000 -2.036 -.556 
PEG-HCuSNPs + 
Laser 
-.7105 .2170 .068 -1.451 .030 
PEG-HCuSNPS-DOX 
+ Laser 
-1.9555* .2170 .000 -2.696 -1.215 
HAuNP-DOX + Laser .0187 .2170 1.000 -.721 .759 
HAuNP-DOX + Laser 
DOX .0083 .2170 1.000 -.732 .748 
DOX/CU2+ -1.0622* .2170 .001 -1.802 -.322 
PEG-HCuSNPS -.3267 .2170 .879 -1.067 .413 
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PEG-HCuSNPs-DOX 
+ Laser 
-1.1642* .2170 .000 -1.904 -.424 
DOX + Laser -.2167 .2170 .990 -.957 .523 
DOX/CU2+ + Laser -1.3150* .2170 .000 -2.055 -.575 
PEG-HCuSNPs + 
Laser 
-.7292 .2170 .056 -1.469 .011 
PEG-HCuSNPS-DOX 
+ Laser 
-1.9742* .2170 .000 -2.714 -1.234 
HAuNP-DOX -.0187 .2170 1.000 -.759 .721 
*. The mean difference is significant at the 0.05 level. 
 
   The total effect of PEG-HCuSNPs-DOX on cell viability was evaluated using 
3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay. As shown 
in Figure 7a, NIR laser exposed PEG-HCuSNPs-DOX exhibited the highest 
anti-cancer effect within the concentration of 0.002–0.78 µg/mL DOX 24 h after 
treatment. The IC50 of PEG-HCuSNPs-DOX combining NIR laser treatment was 0.11 
µg/mL DOX. The IC50 of PEG-HCuSNPs-DOX without NIR laser treatment was 0.21 
µg/mL DOX. Comparatively, the IC50 of PEG-HCuSNPs with and without laser and 
was 0.24 and 2.07 µg/mL in DOX, respectively. The administration of NIR laser 
drastically decreased the viability for cells treated with PEG-HCuSNPs and 
PEG-HCuSNPs-DOX when compared with the non-laser groups at comparative  
concentration. Besides, the IC50 of HAuNPs-DOX on A549 cells with laser (2.0 
W/cm2, 15 s) dose was 2.2 µg/mL DOX, while the IC50 of PEG-HCuSNPs-DOX with 
the same laser dose was 0.11 µg/mL DOX, significantly less than the former 
treatment.  
Further, we used propidium iodide ( PI ) staining to test whether the nanoparticles 
could bring quick damage to cell membrane upon NIR laser administration because PI 
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is a fluorescence marker permeable to porous cell membrane and staining nuclei 
selectively. For the PEG-HCuSNPs-DOX group, the ratio of the PI stained cells to the 
total cells immediately after the NIR laser irradiation was much higher than that of 
PBS control, PBS with laser treatment or even free DOX under identical experimental 
condition (Figure 7b). In addition, the HAuNPs-DOX with laser treatment didn’t show 
significant difference from the PBS control group. It should be noticed that the laser 
induced cell death by PI staining at 4 h after laser treatment was less effective than 
that from the cell viability assay at 24 h after treatment.  This result indicated that 
laser-induced instantaneous ablation to the cell membrane was only one among 
various modalities that PEG-HCuSNPs-DOX caused cancer cell death. Other 
modalities also played important role in causing cell death progressively and 
accumulatively, including the DOX or DOX/Cu2+ complex induced toxicity and ROS 
species. 
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Figure 7. (a) and (b) 24-h viability of A549 cells exposed to different concentration of 
nanoparticles or DOX with or without NIR laser irradiation ( 2.0 W/cm2, 15 sec) by 
MTT assay. Data are plotted as the percentage of viable cells compared to untreated 
controls. Each value represents mean ± SD (n = 3). (c) Percentage of PI stained A549 
cells exposed to different treatment of 0.5 µg/mL DOX equivalent after 4-h incubation 
followed successively by NIR laser irradiation ( 2 W/cm2, 15 s). The control group 
was treated with PBS. (*P< 0.05 as compared with control. Percentage = PI stained 
cells/total cells counted × 100%, n=3 )  
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SUMMARY AND CONCLUSIONS 
In summary, NIR laser controlled anticancer nanocomposite was achieved by 
modification of PEG-HCuSNPs with DOX through chelating interaction. The 
nanocomposite was capable of pH-sensitive drug release, photothermal conversion, 
and generating ROS in response to NIR laser irradiation. With the NIR laser 
responsive multi-functions, highly controlled and effective cancer killing performance 
was achieved. The current work sheds a considerable light on the smart antitumor 
materials by NIR laser control for transdermal cancer therapy. 
METHODS 
Chemicals. Doxorubicin hydrochloride and Dulbecco's Modified Eagle Medium 
(DMEM) were purchased from AK scientific and Lonza, respectively. 
Lysotraker®Blue DND-22 and propidium iodide were supplied from Life 
Technologies. A549 cell line was obtained from American Type Culture Collection 
(ATCC). All the other chemicals were bought from Sigma-Aldrich without further 
purification. The water was purified by using a Milli-Q Synthesis system (Millipore) 
with the resistivity higher than 18.2 MΩ·cm.  
Materials Preparations. HCuSNPs was synthesized according to the previous 
reports.6,13 Briefly, 0.24 g poly(vinylpyrrolidone) and 25 mL sodium hydroxide 
aqueous solution (pH 9.0) were successively added into 25 mL 0.05 mM copper 
chloride aqueous solution, and the mixture was stirred vigorously at room temperature. 
Subsequently, 2.0 mL 0.10 M hydrazine hydrate solution was added, and suspension 
was formed after reaction for 5 min. Then, 0.266 mmol sodium sulfide was added to 
the suspension and stirred at 60 °C for 1 h. The formed HCuSNPs was collected by 
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centrifuging at 11,000 rpm for 10 min, washing three times with pure water and 
suspending in 5 mL pure water. 
To prepare PEG-HCuSNPs-DOX, 20 µL thiolated PEG was added to 5 mL 
aqueous dispersion of 18 mg HCuSNPs and stirred overnight at 1000 rpm. The 
resultant PEG-HCuSNPs was washed three times by centrifuging at 12 000 rpm for 10 
min for three times. Then, 1 mL 1 mg/mL Doxorubicin hydrochloride aqueous 
solution was mixed with the above dispersion containing PEG-HCuSNPs and stirred 
at 1000 rpm for 24 h. After washing with water for three times, PEG-HCuSNPs-DOX 
was obtained. 
Characterizations. To prepare samples for transmission electron microscope 
(TEM) observations, the corresponding materials were ultrasonicated in pure water 
until homogeneous suspension was formed, and the resulting suspension was then 
dropped onto a nickel micro grid, followed by drying in air. TEM observations were 
respectively performed on a JEOL 2100EX microscope operating at an accelerating 
voltage of 100 kV. DLS analysis was proceeded with the Malvern® nanoseries 
Nano-ZS90 nanoparticle size analyzer. UV–visible–NIR absorbance spectra were 
obtained with a Beckmann Coulter DU800 UV–visible–NIR spectrophotometer with a 
quartz cuvette of 1.0 cm optical path length in the transmission mode employing pure 
water as the reference standard. Circular Dichroism spectra were acquired by Jasco 
J-810 Circular Dichroism spectropolarimeter (163~900 nm). Fluorescent spectra were 
measured by SpectraMax Multi-Mode Microplate Readers. 
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The DOX loading efficiency was calculated from the weight of DOX component 
detached from the PEG-HCuSNPs-DOX. The washed PEG-HCuSNPs-DOX was 
mixed with 0.5 mL of 10 mM EDTA and 5 µL of 2 M HCl and incubated at 60 °C for 
1 h. Then, the dispersion was centrifuged at 12000 rpm for 10 minutes. The 
supernatant was collected and analyzed by fluorescent spectroscopy to determine the 
weight of DOX extracted. The DOX loading efficiency was calculated via the 
following equation: 
%100×=
−HCuSNPsPEG
DOX
DOX W
W
E                 (1) 
where EDOX represents the DOX loading efficiency, WDOX stands for the weight of 
DOX extracted from the nanoparticles, and the WPEG-HCuSNPs-DOX shows the weight of 
PEG-HCuSNPs added. 
Cell Culture. A549 cell line was cultured in DMEM media, supplemented with 
10% fetal bovine serum (FBS), L-glucose, glutamine, 100 U/mL penicillin and 100 
µg/mL streptomycin.    
In Vitro Release. In vitro release of DOX from the as-prepared nanoparticles by 
adding 10 mg PEG-HCuSNPs-DOX in a dialysis tube (1000 Da cut off; 
Sigma-Aldrich), placing the tube in 100 mL of phosphate-buffered saline (PBS, pH 
7.4, 10 mM) containing 10% BSA, and shaking constantly at 150 rpm at 37°C. The 
NIR laser was administered as needed after taking out the sample from the dialysis 
tube at 2.0 W/cm2 for 15 s at a time interval of 1 h. The in vitro DOX release was 
continued for 4 h. The release medium was replaced with a fresh one at a determined 
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interval to maintain sink conditions. The amount of released DOX was monitored by 
fluorescent measurement. The fluorescent emission peak at λ = 590 nm under 
excitation light (λ = 485 nm) of each solution was recorded to determine the released 
DOX amount. As a comparison, in vitro release was proceeded identically without 
NIR irradiation.All measurements were performed in triplicate. 
MTT Assay. Cell viability was measured by the 
3-[4,5-dimethylthylthiazol-2-yl]-2,5 diphenyltetrazolium bromide (MTT) method. 
Briefly, A549 cells were seeded in 96-well plates at a density of 5 × 103 cells per well 
and incubated for 24 h prior to use. The cells were respectively incubated with blank 
PEG-HCuSNPs, PEG-HCuSNPs-DOX, and free DOX at equivalent drug 
concentrations ranging from 50 nM to 15 000 nM for 4 h. After replacing the culture 
medium with FBS-free DMEM and irradiation with NIR laser at 2 W/cm2 for 15 s, the 
FBS-free DMEM was substituted with DMEM containing 10% FBS and the cells 
were further incubated for 24 h. Then, MTT tetrazolium salt (0.25 mg/ml) was added 
to each well and incubated in CO2 incubator at 37°C for 4 h. Finally, 150 µL DMSO 
was added to each well dissolve formazan crystals and the UV–vis absorbance peak at 
570 nm was monitored by a plate reader. 26  
ROS Assay A549 cell line was cultured in the coverglass chambers at a 
concentration of 20,000 per well, and free DOX, DOX/Cu2+ complex (DOX:Cu2+ = 
1:1), PEG-HCuSNPs, and PEG-HCuSNPs-DOX were respectively added to each well. 
The final concentration of DOX was 0.5 µM, and the amount of PEG-HCuSNPs was 
kept the same in the wells. After incubating for 4 h, the drug-containing medium was 
replaced with new one and irradiated with NIR laser (900 nm, 2 W/cm2, 15 s) . Then, 
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the medium was substituted with 1 mM DFCH-DA medium and incubated for 30 min. 
After washing with PBS for 3 times, the wells were observe by using the fluorescent 
microscope. 
To determine the ROS level in A549 cells, A549 cell line was cultured in the 
96-well plate at a concentration of 10,000 per well. Then, the cells were treated 
identically by replacing the cell culture medium with DMEM, incubated for 3 h, 
changing the culture medium with pre-warmed freshmedium, adding samples, 
incubated for 4h, replacing medium with DMEM, exposed with corresponding light 
irradiations, substituting the medium with 1 mM DFCH-DA medium, incubated for 30 
min, washing with PBS for 3 times, adding 100 µL cell lycis buffer. Finally, the 
treated specimens were subjected to fluorescent test (excitation λ = 480 nm, emission λ 
= 530 nm) to measure the protein content. As a comparison, DMEM containing 5 mM 
NAC was applied as the cell culture medium and tested through the same procedure. 
PI exclusion assay. A549 cell viability was determined by staining the cells with 
propidium iodide according to the manufacturer's instructions. In a typical procedure, 
the A549 cells were seeded into 96-well culture plates at a concentration of 1.5 × 105 
cells per well and incubated for 24 h to allow cell attachment. The cells were 
respectively administered with free DOX, PEG-HCuSNPs-DOX, and PEG-HCuSNPs 
at equivalent drug concentrations (5 µM) for 4 h. The washing procedure is the same 
as MTT assay. After NIR laser irradiation, the cells were collected by trypsinization 
using a 0.125% trypsin solution. The cells collected were washed twice with PBS (pH 
= 7.4) and re-suspended in 100 µL PBS at a density of 1×105 cell mL–1. Subsequently, 
5 µL of propidium iodide solution (100 µg mL–1) and 400 µL of PBS solution were 
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successively added to the cells. The cells were further incubated for 5 min in darkness, 
and the total number of the cells stained was counted with a cellometer (Nexcelom 
vision). 
Intracellular Uptake. For the PEG-HCuSNPs-DOX uptake study, 12-well 
plates were seeded with A549 cells at 2 × 105 per well, and the cells were allowed to 
attach for 24 h. The medium was replaced with 1 mL of medium containing 
PEG-HCuSNPs-DOX or DOX solution (final Dox concentration 5 µM), and the 
samples were incubated for a determined time period (0.5 h and 2 h). The cells were 
washed three times with PBS buffer to remove the excess drug component, and then 
the cells were lysed in 100 µL of cell lysis buffer for 10 min. 10 mL portion of the 
resultant cell lystate was used to quantify the protein concentration through the BCA 
protein assay. The remained cell lystate dispersion was mixed with 0.2 mL of acidified 
methanol solution (0.1 M HCl in 90% methanol) and centrifuged at 16800 rpm for 10 
min. The supernatant was extracted and subjected for fluorescent spectroscopy to 
analyze DOX level. The fluorescent emission peak at λ = 591 nm was detected under 
excitation λ = 485 nm. The data were normalized to per milligram cell protein. 
Intracellular Elimination. For the PEG-HCuSNPs-DOX elimination study, 
12-well plates were seeded with A549 cells at 2 ×105 per well, and the cells were 
allowed to attach for 24 h. The medium was replaced with 1 mL medium containing 
PEG-HCuSNPs-DOX or Dox solution (final DOX concentration 5 µM) and incubated 
for 4 h. The cells were washed three times to remove the free DOX or 
PEG-HCuSNPs-DOX with PBS buffer and continued to incubate with fresh medium. 
 29 
 
Intracellular DOX level was determined after being washed for 12 h, 24 h and 48 h via 
the same method as described in the intracellular uptake assay section. 
Lysotracking. The lysotracking study was carried out by using Lysotraker®Blue 
DND-22. Generally, 8-well cover slide chambers were seeded with A549 cells at 2 
×105 per well, and the cells were left for 24 h to achieve attachment. The cells were 
incubated for 4 h with 0.5 µg/mL PEG-HCuSNPs-DOX or PEG-HCuSNPs-DOX plus 
laser ( 2.0 W/cm2, 15 s) at the end of incubation. Then the initial medium was 
removed from the chamber, and the pre-warmed probe-containing medium (37°C) was 
added and incubated for 30 min. The cells were washed with phenol red-free DMEM 
for 3 times, and characterized with fluorescent spectroscopes by monitoring the 
emission peak at λ = 424 nm under excitation light of λ = 373 nm.  
All data were expressed as mean SD and IC50 values were calculated by using 
nonlinear regression analysis. The statistical significance was determined using a t test. 
A p value less than 0.05 (i.e., p < 0.05) was considered to indicate statistical 
significance for all comparisons. 
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Abstract 
Copper sulfide with near-infrared light absorption property is recently attracting 
broad interest as a photothermal carrier for smart cancer therapy. Lipophilic copper 
sulfide nanoparticle is preferred for high performance biomedical applications due to 
the high affinity with tissues. But it requires complex multi-step synthetic process 
under severe condition. Here, synthesis of hydrophobic copper sulfide possessing 
surface plasmon resonance was retained by direct dry grinding of copper(II) 
acetylacetonate with sulfur under ambient environment. The formed CuS 
nanoparticles were in uniform size of ~10 nm, and they were monodispersed in pure 
chloroform. Each covellite CuS nanocrystal surface was modified with oleylamine 
through hydrogen bonding between sulfur atoms and amine groups of oleylamine. 
While these oleylamine capped CuS nanoparticles showed uniform morphological 
features, they demonstrated near-infrared light absorption for photothermal 
applications. The facile and mild synthetic methodology described here opened a 
powerful pathway for the design and preparation of photothermal lipophilic copper 
sulfide nanomaterials for smart cancer therapy. 
KEYWORDS: Copper sulfide; oleylamine; nanoparticle; lipophilicity; 
photothermal therapy. 
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1. INTRODUCTION 
Copper sulfide (CuS) nanocrystals with determined vacancies have recently 
demonstrated to be capable of absorbing near-infrared (NIR) light irradiation (650–
900 nm) [1] and instantaneously converting into local heat. This unique property has 
attracted broad interest for a variety of scientific and technological applications such 
as solar cells, electroconducting electrodes, sensors, and clinics.[2–4] Notably, the 
NIR light is able to penetrate through normal tissues with minimal thermal injury.[5] 
The photothermal conversion effect of the CuS nanoparticles is independent of the 
surrounding environment.[6,7] These features are especially useful for controlled drug 
delivery and photothermal cancer therapy.[8–10] 
For the synthesis of CuS nanoparticles with desired nanostructures, a series of 
approaches have been developed, such as hydrothermal [11], solvothermal 
method [12], solid-state reaction [13], microemulsion[14], and reflux 
condensation [15] have been developed. In order to endow the CuS nanoparticles with 
NIR absorption, the as-prepared nanoparticles are usually further oxidized to produce 
vacancies in the crystalline structures.[16] One of the most commonly used method is 
based on the reaction of water soluble copper (II) salt and sodium sulfide as the 
precursor at 90 °C through wet chemistry. The formed citric acid capped CuS 
nanoparticles were applied as a photothermal coupling agent for PTA of cancer 
cells in vitro and in vivo under the laser irradiation (808 nm, 16 W/cm2 and 24 
W/cm2).[1] Alternatively, spherical copper (I) oxide nanoparticle aggregation was 
used as an sacrificial template and it was hydrothermally treated in the presence of 
polyvinylpyrrolidone (PVP) as a capping agent. Through Kirkendall effect, vacancies 
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were introduced to CuS, forming hollow CuS nanospheres with surface plasmonic 
performance.[6] In addition, the controllable hydrothermal approach was employed to 
develop hydrophilic flower-like CuS superstructures with the assistance of PVP (K30, 
0.2 g/mL) at 180 °C for 48 h. The resulting nanostructured CuS was used for ablation 
of cancer cells upon 980 nm laser irradiation.[8] Unfortunately, these methodologies 
generally involved complicated processes as well as excess toxic reagents, which 
caused severe environmental pollution. 
Recently, lipophilic nanomaterials have been developed for their drug delivery 
into hydrophobic tissues such as brain and vascular tissues. To retain CuS 
nanoparticles dispersible in organic phase, hot injection [17], cation exchange, [18] 
and solventless approach[19] have been reported. Among them, hot injection method 
based on high temperature reaction of copper (II) acetylacetonate and elemental sulfur 
or sulfur provider (e.g., dodecanethiol) has been widely used. However, the lipophilic 
CuS nanoparticles synthesized by these methods are not able to absorb NIR light. 
Thus, they require additional complex oxidization treatment to show photothermal 
performance. 
In this paper, lipophilic CuS nanoparticles were synthesized by directly grinding 
copper (II) acetylacetonate with sulfur in oleylamine at room temperature. Within a 
few minutes of grinding in the ambient environment, the CuS nanoparticles were 
attained in high yield. The resulting CuS nanoparticles were in uniform particle size of 
~10 nm. Each nanoparticle had fine CuS nanocrystal core, which was capped with 
oleylamine through hydrogen bonding between sulfur atom and amine group of 
oleylamine. These nanoparticles were readily dispersible in chloroform without 
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aggregation. While these CuS nanoparticle showed almost identical features as those 
synthesized by the traditional solution based solvothermal approach, the current CuS 
nanoparticles demonstrated distinguished absorption of NIR light, capable of 
photothermal applications. Compared with the traditional solvothermal method, this 
synthetic approach did not need excess toxic chemicals. And this process can scale up 
easily. The unique facile synthetic method presented here sheds a considerable light on 
the synthesis high performance lipophilic CuS nanoparticles for smart photothermal 
therapy. 
 
2. EXPERIMENTAL 
Materials. Chloroform (>99%), cyclohexane (>99%) and ethanol (>99%) were 
purchased from Fisher Scientific. Oleylamine, Sulfur, and copper(II) acetylacetonate 
were bought from Sigma-Aldrich. All chemicals were used as received.  
Synthesis of CuS Nanoparticles. To dry grinding synthesis of CuS 
nanoparticles, 0.131 g of copper (II) acetylacetonate, 0.016 g sulfur and 2 mL 
oleylamine were thoroughly mixed by grinding for 5 min using a mortar and a pestle. 
During the grinding process, the mixture gradually became brown translucent liquid. 
Then, the liquid was transferred into a round bottom flask and stirred at 70°C for 30 
min, upon which the mixture color further turned from brown to green. Subsequently, 
the resulting mixture was dispersed in 20 mL chloroform and centrifuge for 30 min at 
11,000 rpm. The collected precipitation was dispersed in 10 mL chloroform, and 50 
mL ethanol was added to precipitate the formed nanoparticles. These nanoparticles 
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were collected by centrifugation and washed by excess ethanol repeatedly to remove 
the remaining surfactant. After vacuum drying at room temperature, lipophilic CuS 
nanoparticles were obtained. 
As a comparison, CuS nanoparticle were prepared by traditional solution based 
hot injection approach. 0.131 g copper (II) acetylacetonate was dissolved in a mixture 
of 1 mL oleylamine and 3 mL chloroform, and 0.016 g sulfur was dissolved in 3 mL 
oleylamine. The sulfur solution was dispersed in 10 mL cyclohexane and stirred at 
70 °C for 10 min. After slowly injecting the copper (II) solution into the cyclohexane 
solution and stirring at 1,000 rpm at 70 °C for 30 min, the mixture solution gradually 
transformed from brown to green. The powder collected by centrifugation at 11,000 
rpm for 30 min was then dispersed in 10 mL chloroform and mixed with 50 mL 
ethanol to purify the resultant CuS nanoparticle. These purified nanoparticles were 
further washed with ethanol for several cycles to exclude the excess surfactant and 
dried in vacuum oven overnight.  
Transmission electron microscope (TEM). To prepare samples for 
transmission electron microscope (TEM) observations, the corresponding materials 
were suspended in chloroform and then dropped onto a carbon coated nickel micro 
grid, followed by drying in air in fume hood. TEM observations were performed on a 
JEOL 2100EX microscope operating at an accelerating voltage of 100 kV.  
Fourier transform infrared (FT-IR) spectra were measured on a Nicolet 
Nexus 670 spectrometer using KBr pellets.  
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Powder X-ray diffraction (XRD) patterns of the synthesized nanoparticles 
were recorded on Rigaku Ultima IV multipurpose X-ray diffractometer with a CuKa (λ 
= 0.15405 nm) radiation source. The X-ray tube current was 100 mA with a tube 
voltage of 40 kV. Each sample was scanned at a scan rate of 0.5° with resolution of 
~0.02° from 2θ of 20° to 70°.  
Dynamic light scattering (DLS). DLS analysis was proceeded with the 
Malvern® nanoseries Nano-ZS90 nanoparticle size analyzer using a 1.0 cm path 
length 4-way glass cuvette.    
UV−Vis−NIR Spectroscopy.  Extinction spectra of all nanoparticles were 
recorded with a PerkinElmer Lambda 1050 UV–visible–NIR spectrophotometer with a 
quartz cuvette of 1.0 cm optical path length in the transmission mode employing pure 
chloroform as the reference standard.   
X-ray Photoelectron Spectroscopy (XPS). A Measurement was carried out on a 
PHI 5500 system and Al Kα radiation. Multipak versions 6.1 as well as XPS Peak 4.0 
software were utilized for analysis and curve fitting respectively. A combination of 
Lorentzian and Gaussian functions was used for the least squares curve fitting. 
 
3. RESULTS AND DISCUSSION 
The TEM image of the CuS nanoparticles synthesized by the dry grinding 
process is shown in Fig. 1a. Many nanoparticles were clearly observed. These metallic 
nanoparticles were mainly in cubic geometry, and they were monodispersed. Some 
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minor aggregation was caused by the evaporation of chloroform component during the 
TEM sample preparation process, which was a common situation. Calculated based on 
at least 300 particles, the average size for these CuS nanoparticles was ~10 nm. This 
result matched well with the hydrodynamic particle diameter of the DLS analysis (Fig. 
2), indicating excess surfactant was cleared and monodisperse fine nanoparticles 
remained. As a comparison, CuS nanoparticles were prepared through the previously 
reported solution based technique. As shown in TEM (Fig. 1b), the formed CuS 
nanoparticle size was ~9 nm on average, and they were similar as the above 
nanoparticles obtained by the dry grinding process. The solution based approach 
derived nanoparticles were more spherical, because the liquid environment inhibited 
directional crystal growth of the nanocrystals. Therefore, the dry grinding synthesis 
approach achieved the fine nanocrystals, which was almost identical to the traditional 
solution based method. 
The XRD pattern of the powder sample prepared by the dry grinding method 
presented clear peaks at 29.3°, 31.8°, 47.9 °, 52.7 °, and 59.3° (Fig. 3a), which were in 
fair agreement with (102), (103), (110), (108), and (116) plane of covellite phase CuS 
(powder diffraction file or PDF# 06-0464). The broad peaks inferred the nanoscale 
nature of the sample.[20] The crystal size calculated based on (110) plane was ~ 7.73 
nm. This size was relatively smaller than the particle size measured in TEM images 
(10 nm), because a minor amorphous oleylamine layer was modified on the 
nanocrystal surface. These characteristic peaks were identical to those prepared 
through the solution based method. Therefore, the current CuS nanoparticles prepared 
through dry grinding process formed high quality fine covellite CuS nanoparticles. 
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XPS spectra of the as-prepared CuS nanoparticles were summarized in Fig. 4. 
The Cu 2p XPS spectrum exhibited 2p3/2 peak at 932.0 eV and 2p1/2 peak at 952.2 eV, 
which were typical peaks for Cu(II) in copper sulfide.[21] The C 1s peak was resolved 
as two peaks located at 284.6 eV and 285.7 eV, which respectively corresponded to 
the hydrocarbon (C-C, C-H) in oleylamine and the C-N bond in oleylamine.[22] The S 
2p peak of the CuS nanoparticles consisted of two distinct peaks. The one at 161.5 eV 
originated from typical sulfide bond, and the doublets at 162 eV and 163.5 eV 
demonstrated the formation of S–H bonds.[23] These peaks matched well with the 
XPS spectra obtained from the CuS nanoparticle fabricated via the hot-injection 
method (Fig. 5), supporting that the current CuS nanoparticles were capped with 
oleylamine. Hydrophilic Sulfur atoms in CuS was qualified electron acceptors.[16] 
Although it hardly interacted with the hydrophobic alkyl terminals of the oleylamine, 
it readily accepted electron from the amine group in oleylamine, forming S–H bonds.  
In the FTIR spectrum of the resultant CuS nanoparticles (Fig 6), the broad band 
at ~3450 cm–1 was assigned to N-H stretching vibration of the amine group in 
oleylamine,[24] the two bands at 2922 cm–1 and 2852 cm–1 were assigned to the 
asymmetric (νas) and symmetric (νs) stretching vibrations of methylene (CH2=CH) in 
the alkyl chain of oleylamine, the bands centered at 1634 cm–1 was attributed to N-H 
bending vibration.[25-27] All of these characteristic bands were in fair agreement with 
the FTIR spectrum of pure oleylamine. Hence, oleylamine was capping on the CuS 
nanoparticles. 
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Interestingly, the dry grinding synthesized CuS nanoparticles demonstrated broad 
NIR absorption peaks centered at ~ 1100 nm (Fig. 7), which was very close to the 
traditional CuS nanoparticles prepared by solution based technique. This strong 
absorption suggested that the current CuS nanopaticles possessed localized surface 
plasmon resonances for photothermal ablation applications.  
Usually, it requires a liquid environment, high temperature, and N2 protection to 
achieve fine CuS nanoparticles. The liquid environment allows oleylamine to form 
micelles to direct the nucleation as well as growth of nanocrystals and prohibit 
nanoparticle agglomeration. Meanwhile, high temperature accelerates the reaction and 
inert environment prevents over oxidation of CuS to damage NIR absorbance (peak 
absorbance < 1150 nm).[16] In the current study, it was proved that such conditions 
were not mandatory for the synthesis of monodispersive fine CuS nanoparticles. The 
grinding process realized fully contact of copper (II) salt with oleylamine for 
complexation. The copper(II) salt complexed oleylamine consisted of hydrophilic salt 
terminal and long alkyl chain groups, which still formed micelle structure and control 
the crystal growth. Moreover, the existence of oxygen in the reaction process induced 
the formation of vacancy in CuS crystals, resulting in NIR absorption. Although 
further work is needed to clarify the actual reaction mechanism of the dry grinding 
synthesis approach, this method attained monodisperse fine CuS nanoparticles with 
surface plasmonic performance in a facile and mild process. 
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Fig. 1. TEM micrograph for CuS nanoparticles synthesized by the dry grinding 
approach (a) and the traditional hot-injection method (b). Bars: 20 nm. 
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Fig. 2. Dynamic light scattering (DLS) analysis of the oleylamine coated CuS 
nanoparticle deprived by the dry grinding approach (a) and the traditional hot-injection 
method (b). 
 
Fig. 3. XRD spectra of the CuS nanoparticles synthesized through the dry grinding 
approach (a) and the traditional hot-injection method (b). 
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Fig. 4. X-ray Photoelectron Spectroscopy (XPS) spectra of CuS synthesized by the dry 
grinding approach. (a) C 1s, (b),Cu 2p, and (c) S 2p regions. 
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Fig. 5. XPS spectra of CuS synthesized by the traditional hot-injection approach. (a) C 
1s, (b) Cu 2p, and (c) S 2p regions. 
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Fig. 6. FT-IR spectra of CuS synthesized by the dry grinding approach and the 
traditional hot-injection method. 
  
Fig. 7. Visible-NIR spectra of CuS nanoparticle (1 mM) dispersion in chloroform 
synthesized by the dry grinding approach and the traditional hot-injection method. 
 
4. CONCLUSIONS 
Synthesis of monodisperse CuS nanocrystals was achieved by a facile one step 
dry grinding process. The nanoparticles were composed of covellite phase CuS, and 
the particle size was finely controlled as ~10 nm. The CuS nanoparticle surface was 
capped with oleylamine by hydrogen bonding between sulfur atoms with amine group 
of oleylamine. While the resultant CuS nanoparticles were highly comparable with 
those prepared through traditional solvothermal method, the current approach was 
carried out at ambient condition and decreased use of toxic solvents. This 
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environmental benign opened a facile pathway for the large-scale production of 
photothermal nanocrystals for applications smart drug delivery.  
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ABSTRACT: Chemo therapeutic drug-caused side effects are commonly seen in 
clinical practice due to nonspecific toxicity and low therapeutic efficiency. Herein, we 
reported a cancer chemo-photothermal multifunctional drug delivery system. 
Polyethylene glycol decorated mesoporous silica nanoparticles entrapping CuS 
nanoparticles (PEG-CuS@MSNs) were successfully synthesized and characterized for 
the drug delivery application. Doxorubicin (DOX)-loaded PEG-CuS@MSNs showed 
laser stimulated and pH-responsive properties. In vitro cell experiments demonstrated 
that DOX-loaded PEG-CuS@MSNs combining laser exposure achieved the highest 
rate of death of A549 cells, in comparison to that of PEG-CuS@MSNs-DOX alone. 
These findings provided a promising drug delivery system for cancer combinatorial 
therapy, which could significantly reduce drug dose and improve patient compliance. 
 
KEYWORDS: magnetism, mesoporous silica nanoparticles, photothermal therapy, 
doxorubicin 
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INTRODUCTION 
Cancer chemotherapy is often frightening because of not only the side effects but also 
the high possibility of recurrence rate. In clinical practice, chemotherapy usually 
accompanies with surgery, radiotherapy, etc. However, the 5-year relative survival 
rate is still low, 68% for all cancers diagnosed between 2003 and 2009 in the United 
States.[1] Various methods have been developed in addition to chemotherapy, such as 
nano technique, targeted delivery, photothermal therapy, photodynamic therapy, etc.[2] 
One highlighted trend is the application of nanotechnology, which delivers drug more 
precisely at cancer cells and brings less damage to normal cells, thus diminishing side 
effects. Beside, photothermal therapy can ablate cancer cells. Combination of chemo 
and photothermal therapy with targeting feature into a nano delivery system would be 
a practical and efficient solution worth trying.  
Copper sulfide nanoparticles (CuS NPs) are a new class of photothermal sensitizer. 
Their light absorption is not affected by the surrounding environment.[3, 4] They exhibit 
stable light absorption towards near-infrared (NIR) light irradiation (650–900 nm),[5] 
which will bring minimal thermal injury to normal tissues.[6] Immediately upon NIR 
light absorption, CuS NPs generate heat and photothermally ablate tumor in vivo after 
intratumor[7, 8] or intravenous injection.[9]  
Although CuS NPs are promising, when applying to drug delivery, the 
nanoparticle itself has limitation as a platform.[10] Since the surface is only one layer to 
attach the chemicals, the loading efficiency is limited. To address this problem, 
mesoporous silica is chosen considering its large pore size and high surface area. 
Moreover, the technique of synthesizing a layer of mesoporous silica on the surface of 
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inorganic template is relatively mature. There have been many reports on the 
preparation of nanocrystals coated with mesoporous shells such as gold nanorods, [11] 
iron oxide,[12] manganese oxide nanoparticle[13], graphene nanosheet,[14] etc. However, 
studies on CuS NPs coated with mesoporous silica have not been reported. 
In this study, a chemo photothermal drug system was formulated to increase drug 
loading efficiency. Specifically, mesoporous silica spheres containing CuS NPs in the 
core and DOX loaded in the silica channels (PEG-CuS@MSNs-DOX) were prepared. 
Furthermore, these mesoporous silica spheres were applied to photothermal therapy. A 
procedure for the synthesis of the CuS@MSNs-DOX is shown in Scheme 1. 
 
Scheme 1. Schematic illustration of the synthesis process of PEG-CuS@MSNs-DOX. 
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EXPERIMENTAL SECTION 
2.1. Chemicals. Doxorubicin hydrochloride and Dulbecco's Modified Eagle 
Medium (DMEM) were purchased from AK scientific and Lonza, respectively. All the 
other chemicals were bought from Sigma-Aldrich without further purification. The 
water was purified by using a Milli-Q Synthesis system (Millipore) with the resistivity 
higher than 18.2 MΩ·cm.  
CuS nanoparticle preparation. Copper acetylacetonate (0.131 g) and 0.032 g sulfur 
(0.032 g, 1 mmol) and oleylamine (4.0 mL) were thoroughly ground and mixed for 5 
min using a mortar and a pestle. During the grinding process, the mixture became a 
brown, translucent liquid. Then, the liquid was transferred into a round bottom flask 
and heated up to 70°C with magnetic stirring for 1 h. The color of the mixture then 
turned from brown to green. The product was thereafter suspended in 20 mL 
chloroform and transferred into a centrifuge tube and centrifuged for 30 min at 11,000 
rpm. The supernatant was decanted and the precipitated pellet was collected. This 
pellet was suspended with 10 mL of chloroform. Subsequently, 30 ml ethanol was 
added to precipitate the nanoparticles. After centrifugation, the nanoparticles were 
separated from the supernatant. Then wash the nanoparticles twice with ethanol to 
remove the excess oleylamine. The final CuS NPs capped with surfactant were dried 
at room temperature in a high vacuum. The as-prepared nanoparticles are 
re-dispersible in chloroform.  
Synthesis of CuS nanoparticles embedded in mesoporous silica spheres 
(CuS@MSNs). 7.5 mg CuS nanoparticles in chloroform (0.2 mL) were added to a 1.5 
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mL centrifuge tube, and total volume was complemented by chloroform to 0.5 mL. 
The resulting CuS NPs suspension (0.5 mL) was added into 5 mL 0.02 g/mL 
cethyltrimethylammonium bromide (CTAB) aqueous solution and stirred vigorously 
for 30 min. The mixture gradually turned to turbid green color, indicating the 
formation of an oil-in-water microemulsion. Then, the solution was heated up to 60 °C 
for 10 min under stirring to evaporate the chloroform, resulting in a transparent green 
CTAB stabilized CuS NPs suspension. The resultant suspension was added to a 
mixture of 45 mL of water and 0.3 mL of 1 M NaOH solution and the mixture was 
heated up to 70℃ under stirring. Then, 3 mL of ethylacetate and 0.15 mL of 
tetraethylorthosilicate (TMOS) were added to the reaction solution in sequence. After 
10 min, 50 µL of APTES was added and the solution was stirred for 1 h. The 
precipitate was separated by centrifugation and washed with ethanol for 3 times and 
suspended in 20 mL ethanol.  
PEGylation of MSNs. 50 mg of methoxy poly (ethylene glycol) succinimidyl 
glutarate (Mw 2000) dissolved in 20 ml ethanol was added to the as-synthesized 
particles followed by stirring at 40°C for 3 h. The unreacted PEG was removed by 
ethanol and water. The PEGylated particles were dispersed in phosphate buffer 
solution (PBS, 10 mM, pH 7.4). 
Loading of doxorubicin. The loading of doxorubicin for in vitro experiment were 
performed as follows: PEGylated MSN solution (5 mL, 4 mg/mL) and doxorubicin 
ethanol solution (5 mL of 2 mg/mL) were mixed by stirring at 300 rpm for 24 h. Then, 
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the nanoparticles were isolated by centrifugation and vacuum dried overnight. 
Fully-dried sample was suspended into 10 mL of 100 mM PBS buffer (pH 7.0).  
Characterizations. To prepare samples for transmission electron microscope (TEM) 
observations, the corresponding materials were ultrasonicated in pure water until 
homogeneous suspension was formed, and the resulting suspension was then dropped 
onto a nickel micro grid, followed by drying in air. TEM observations were 
respectively performed on a JEOL 2100EX microscope operating at an accelerating 
voltage of 100 kV. DLS analysis was proceeded with the Malvern® nanoseries 
Nano-ZS90 nanoparticle size analyzer. UV–visible–NIR absorbance spectra were 
obtained with a PerkinElmer Lambda 1050 UV–visible–NIR spectrophotometer with a 
quartz cuvette of 1.0 cm optical path length in the transmission mode employing pure 
water as the reference standard. FT-IR spectra were obtained with Thermos Scientific 
Nicolet 380 FT-IR Spectrometer. X-ray diffraction (XRD) patterns of the produced 
nanoparticles were recorded on a Rigaku Ultima IV multipurpose X-ray diffraction 
system. Fluorescent spectra were measured by SpectraMax Multi-Mode Microplate 
Readers. 
In Vitro Release. In vitro release of DOX from the as-prepared nanoparticles by 
adding 10 mg PEG-CuS@MSNs-DOX in phosphate-buffered saline (PBS, pH 7.4, 10 
mM), and stirred constantly at 500 rpm. The NIR laser was administered as needed at 
900 nm with power density of 2 W/cm2 for 2 min at time points of 1, 4, 8, 12 and 24 h. 
The samples were collected before and after laser irradiation by centrifuge at 15,000 
rpm for 10 min followed by filtration with 0.22 µm filter. The release medium was 
replaced with a fresh one each time to maintain sink conditions. The amount of 
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released DOX was monitored by fluorescent measurement. The fluorescent emission 
peak at λ = 590 nm under excitation light (λ = 485 nm) of each solution was recorded 
to determine the released DOX amount. As a comparison, in vitro release was 
preceded identically without NIR irradiation. All measurements were performed in 
triplicate. 
Cell Culture. A549 cell line was cultured in DMEM media, supplemented with 10% 
fetal bovine serum (FBS), L-glucose, glutamine, 100 U/mL penicillin and 100 µg/mL 
streptomycin.    
Cell uptake of PEG-CuS@MSNs-DOX. 8-well cover slide chambers were seeded 
with A549 cells at 2 ×105 per well, and the cells were allowed to attach for 24 h. The 
medium was replaced with 1 mL medium containing PEG-CuS@MSNs-DOX or Dox 
solution (final DOX concentration 5 µM) and incubated for 4 h. The cells were 
washed three times with PBS to remove the drug. Cell nuclei were stained with 
Hoechst 33258. The cellular fluorescence were obtained as described in the preceding 
paragraph.  
Cytotoxicity. Cytotoxicity was measured by the 3-[4,5-dimethylthylthiazol-2-yl]-2,5 
diphenyltetrazolium bromide (MTT) method. Briefly, A549 cells were seeded in 
96-well plates at a density of 5 × 103 cells/well and incubated for 24 h prior to use. 
The cells were respectively incubated with PEG-CuS@MSNs-DOX, 
PEG-CuS@MSNs, and free DOX at equivalent drug concentrations ranging from 50 
nM to 15000 nM for 4 h. Then the culture medium containing particles was replaced 
with fresh medium and continued incubation for 20 h. Then, MTT tetrazolium salt 
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(0.25 mg/ml) was added to each well and incubated in CO2 incubator at 37°C for 4 h. 
Finally, 150 µL DMSO was added to each well dissolve formazan crystals and the 
UV–vis absorbance peak at 570 nm was monitored by a plate reader.   
In vitro efficiency test was carried out via trypan blue exclusive assay. A549 cells 
were seeded in 12-well plates at a density of 5 × 104 cells/well and incubated for 24 h 
prior to use. 20 µL of PBS control or 20 µL of 2 µg/mL (in Cu2+) nanoparticles 
dispersed in PBS was added into designated wells of the 12 well plate. Then the plate 
was incubated for 4 h. After irradiation with laser (900 nm, 2W/cm2) for 1 min, the 
sample was stained by 0.4 mL trypan blue for 3 min. The stained sample was washed 
twice with PBS, and mixed with 0.4 mL PBS. The in vitro efficiency was observed by 
inverted microscope, and images were taken with a Cannon digital camera.  
All data were expressed as mean SD. The statistical significance was determined 
using a t test. A p value less than 0.05 (i.e., p < 0.05) was considered to indicate 
statistical significance for all comparisons. 
RESULTS AND DISCUSSION 
Oleylamine coated CuS NPs was synthesized with a newly developed facile 
non-solvent method. The TEM image suggested that CuS NPs were in flake shape 
(Figure 1a) with an average size of 12 nm. The lateral view of some particles 
demonstrates thin and rod-like structure, which agreed well with the CuS NPs 
prepared by the complicated multi-step techniques.[15] It was considered that several 
CuS nanoflakes stacked and were wrapped together into one silica nanoparticle during 
the sol–gel reaction (Figure 1b). The average size of CuS@MSN was ~40 nm, 
meeting the practical requirement for drug delivery.[16]. Figure 1c showed the 
 63 
 
PEG-CuS@MSNs nanoparticles (right) turned to purple after loading DOX (left). The 
loading efficiency was as high as 18.4%. 
DLS measurement presented a particle diameter of 58 nm. This was close to the 
TEM result, but it was slightly larger (Figure 2). Because DLS measurement acquired 
hydrodynamic data, and the swollen state of the nanoparticle inevitably became bigger 
than the value at dry shrunk state.[17] 
Zeta potential of CuS@MSN was –36.2 mV. Although the initial nanoparticle 
surfaces are negatively charged, the coating of PEG on the surface brought the zeta 
potential to nearly neutral, ~0.5 mV, which was preferable for drug delivery to the 
negatively charged cell membranes.[18] 
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Figure 1. TEM image of oleylamine-coated CuS NPs (a), and CuS@MSNs (b). The 
red circle, a nanoparticle showing the panel of CuS NPs. The yellow circle, a 
nanoparticle showing the lateral of CuS NPs stacks. A photograph (c) showed 
PEG-CuS@MSNs-DOX (left) and PEG-CuS@MSNs (right).  
 
Figure 2. Hydrodynamic particle diameter of CuS@MSNs by DLS analysis. 
The XRD patterns of CuS@MSNs were exhibited in Figure 3. The typical peak of 
SiO2 was found at 2θ = 21.7° (Figure 3). It also exhibits the CuS (Powder diffraction 
file or PDF#65-3588) characters with 2θ at 29.3° (1 0 2), 31.8° (1 0 3), 32.9° (1 0 6), 
48.0° (1 1 0), 52.7° (1 0 8), 59.3° (1 1 6), 69.4° (1 0 11).  
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Figure 3. XRD pattern of CuS@MSNs. 
The UV-vis-NIR spectra of CuS NPs, and PEG-CuS@MSNs and 
PEG-CuS@MSNs-DOX all showed strong absorbance at the NIR region between 800 
to 1400 nm, which is within photothermal treatment range (Figure 4). However, a 
closer look at the spectra of the silica nanoparticles revealed that there was a slight 
shift in the spectra, which might due to the change in the local refractive index of the 
surrounding medium.[19] In addition, PEG-CuS@MSNs-DOX also exhibited the 
typical absorbance band of Dox. It should be notified a red shift from 490 nm to 516 
nm due to the influence of copper. (There is a detailed discussion on the interaction 
between DOX and copper ion in Chapter 1.) 
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Figure 4. UV-vis-NIR spectra of oleylamine coated CuS NPs (a), PEG-CuS@MSNs 
(b) and PEG-CuS@MSNs-DOX (c). Concentration: 1.5 mM in copper. 
The drug release behavior of PEG-CuS@MSNs-DOX was studied in the pH of 7.4, 
6.0, and 5.0 buffer solutions over a 24-h period (Figure 5). It can be seen that DOX 
release was pH dependent. At pH 5, the 24 h cumulative release of DOX for 
PEG-CuS@MSNs-DOX was 17.9%. At pH 6.0, the released ratio decreased to 12.4%, 
and dropped down to 5.7% when pH increased to 7.4. In addition, the release results 
also indicated that NIR laser irradiation accelerated DOX release in various pH 
conditions. Each time upon laser irradiation for 2 min at 2 W/cm2, released DOX is 
enhanced 1-2 % immediately. The laser-triggered release was well responsive by 
repeating the laser irradiation. The drug release slowed down when the laser was 
switched off. Compared with PEG-HCuSNPs-DOX, the percentage release triggered 
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by laser was much lower. Since DOX was loaded in the channels of MSNs, limited 
proportion of the DOX were drove out of the channel by Cu NPs explosion upon laser 
irradiation. But for PEG-HCuSNPs-DOX, laser irradiation brought devastating 
damage to each nanoparticle, thus the DOX adsorbed or chelated to the surface was 
released significantly. Back to the PEG-CuS@MSNs-DOX, in addition to pH 
sensitive and laser triggered release, the release showed sustained release profile, as 
over a period of 24 h, less than 20% of DOX was released. The triple-module release 
profile, namely pH sensitive, laser controlled and sustained release, presented a 
controlled release manner through which the drug could be specifically and extended 
released at the tumor site either by applying NIR laser or replying on the acidic 
environment of the tumor. 
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Figure 5. Cumulative release profile of PEG-CuS@MSNs-DOX at different pH 
buffers with 1 min of 2 W/cm2 NIR laser irradiation at 1 , 2, 4, 8, 12 and 24 h. Data 
are expressed as mean ± SD (n = 3). 
PEG-CuS@MSNs-DOX was internalized into A549 cells after 2 h incubation. 
PEG-CuS@MSNs-DOX showed strong red fluorescence signal from DOX, despite 
the quenching effect of DOX bond to PEG-CuS@MSNs. The fluorescence of DOX 
was limited in spots scattered throughout the cytoplasm, indicating a distribution in 
endolysosomal vehicles. (Figure 6) In comparison, free dox diffused in both cytoplasm 
and nuclei after 2 h incubation.  
 70 
 
 
Figure 6. Fluorescence images of A549 cells after 2 hour incubation with DOX (a) 
and PEG-CuS@MSNs-DOX (b), respectively. The cell nuclei were stained with 
Hoechst 33258 (blue, the left column). Red, DOX, in the middle column. The overlay, 
in the right column. Scale bar: 50 µm. 
Cytotoxicity was tested by the methyl thiazolyl tetrazolium (MTT) assay in A549 
cells derived from human lung carcinoma cell line (Figure 7). The results showed that 
the cellular viability was estimated to be higher than 71% after 24 h incubation in the 
presence of the PEG-CuS@MSNs or PEG-CuS@MSNs-DOX with Cu concentrations 
of 0−10 µg/mL, indicating a relatively low cytotoxicity within this concentration range 
(Figure 7). The IC50 of free DOX was about 0.12 µg/mL (data not shown) while the 
IC50 of PEG-CuS@MSNs-DOX was significantly higher, 15 µg/mL, because of the 
slow release profile of PEG-CuS@MSNs-DOX. PEG-CuS@MSNs-DOX exhibited 
enhanced toxicity (IC50 = 59 µg/mL of Cu2+) than PEG-CuS@MSNs did (IC50 = 90 
µg/mL of Cu2+).  
 71 
 
 
Figure 7. Cell viability of A549 cells when incubated 4 h with (a) PEG-CuS@MSNs 
or PEG-CuS@MSNs-DOX, with different dosages (n = 4). 
The therapeutic efficacy test in vitro was explored on A549 cells incubated in 
24-well plate. It was observed efficient photothermal ablation of the A549 cells only 
after 1 min irradiation of the 900 nm laser in the presence of the nanoparticles. Also, 
in the trypan blue assay as shown in Figure 7, few cells were dead either after laser 
exposure alone (7b) or after treated with different nanoparticles without laser exposure 
(Figure 7c and 7e). However, almost all the cells were dead after laser irradiation in all 
nanoparticle groups (Figure 7d 7f and 7g). This was attributed to the efficient 
intracellular uptake of PEG-CuS@MSNs-DOX after 2 h incubation.  
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Figure 8. Optical images of A549 cells obtained after the cell viability (trypan blue) 
test. (a) and (b), cells treated with PBS alone and PBS plus NIR laser (900 nm, 2 
W/cm2, 1 min), respectively. (c) and (d), cells treated with PEG-CuS@MSNs alone 
and PEG-CuS@MSNs plus NIR laser, respectively. (e) and (f), cells treated with 
PEG-CuS@MSNs-DOX alone and PEG-CuS@MSNs-DOX plus NIR laser, 
respectively. Scale Bar: 50 µm. (g) Quantification of cell viability of (a-f).  
CONCLUSIONS 
In summary, monodisperse CuS nanocrystals coated in uniform pore-sized 
mesoporous silica nano spheres with an average particle size of 40 nm were 
successfully synthesized. Mesoporous silica spheres adsorbed doxorubicin and 
enabled high drug loading capacity. The release rate of doxorubicin was faithfully 
controlled by pH, laser exposure and the surface property of mesoporous silica. They 
showed photothermal effects on cancer cells upon laser exposure. These mesoporous 
silica nanoparticles provide a facile pathway for versatile biomedical applications. 
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Abstract:  
Transdermal delivery offers an excellent route for drug and vaccine administration. 
Nonetheless, it presents a critical challenge due to the skin’s lipid-rich outer stratum 
corneum layer. Laser ablation perforates epidermis through selective photothermolysis, 
making skin more permeable to hydrophilic and macromolecular drugs such as 
peptides, proteins, and genes. This review summarizes recent applications to laser 
ablation-enhanced transdermal delivery. Needle- and pain-free transcutaneous drug 
delivery via laser ablation provides an alternative approach to achieve local or 
systemic therapeutics.  
Keywords: Laser ablation, Transdermal, Drug delivery, Microporation, Nanoparticle 
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1 Introduction 
The development of transdermal drug delivery systems (TDDS) is attractive because 
skin is the largest organ. TDDS have the distinct advantages over oral administration 
or injections since they directly deliver drugs into the skin or even the systemic 
circulation, avoiding first-pass clearance of liver thus enhancing bioavailability. TDDS 
provide sustained and steady-state pharmacokinetics, therefore decreasing 
administration frequency and improving the patient compliance. Further, TDDS avoid 
the limitation of injections such as pain, accidental needle-sticks, and possible side 
effects due to transiently high plasma drug concentration [1-3].  
However, the skin presents a natural barrier to protect our body from the rough 
environment. It forms multilayers in the epidermis, which include stratum corneum 
(SC), stratum lucidum, stratum granulosum, stratum pinosum, stratum basale from 
topical toward dermis. The SC is the outmost layer and consists of dead keratinocytes 
or corneocytes intercalated with lipids [4]. This 10- to 20-µm thick layer is the 
formidable barrier preventing most drug molecules from permeation. Only lipophilic 
drug with molecular weight (MW) less than 500 Daltons is able to penetrate the skin 
barrier, such as clonidine, fentanyl, and lidocaine [3, 5].  
A variety of methods have been tried to enhance the permeability of the SC. Chemical 
enhancers promote the drug penetration through the SC by disrupting the highly 
ordered bilayer structures of the intracellular lipids in the SC [3]. Conventional 
chemical enhancers such as Azone (1-dodecylazacycloheptan-2-one) as well as newly 
developed biochemical enhancers like peptides are of interest [6, 7]. However, 
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chemical enhancement has been shown little impact on delivery of hydrophilic drugs 
and macromolecules and irritation to living cells in the deeper skin [3]. On the other 
hand, physical enhancement techniques including mechanical and thermal approaches 
have been used to make micrometer dimensions of disruptions to SC structures. These 
micro-scale disruptions create channels of sufficient dimensions for passage of 
macromolecules. The thermal ablation activated by microheaters,[8] radio-frequency 
[9-11], superheated steam ejectate [12] or laser [13-16] is non-invasive technique to 
selectively remove small portions of the SC. These perforations are temporary, since 
the layers of the SC are continually replaced through the natural process of 
desquamation [8]. Some of the physical enhancement technologies have been applied 
in clinical trials for TDDS such as BA058 transdermal microneedle patch [17], 
transdermal basal insulin patch with microporation [18], teriparatide acetate TDDS 
transdermal [19], and electroacupuncture for opioid detoxification [20].  
Laser ablation enhancement belongs to a physical approach that utilizes laser to 
perforate or remove the SC barrier in order to enhance the drug penetration. Water and 
pigments in the skin absorb the laser light energy and transform it into heat to achieve 
theromolysis of the skin. The heating duration must be controlled within microseconds 
in order to avoid heat propagation to deeper tissues [21]. The laser ablation approach 
enables precise control of depth of skin permeation, having the potentials for 
percutaneous delivery of biomacromolecules such as peptides, proteins, vaccines, 
DNAs [15]. In this review, we will focus on recent progresses of laser ablation 
enhanced TDDS. 
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2 Direct laser ablation enhancement 
Although many types of laser with a broad wavelength range (193 – 10,600 nm) are 
available in clinical practice such as ruby laser, neodymium:yttrium-aluminum-garnet 
(Nd:YAG) laser, alexandrite laser, CO2 laser and erbium:yttrium-aluminum-garnet 
(Er:YAG) laser (Table 1), only a few are applied to transdermal delivery so far. 
Pulsed CO2 and Er:YAG laser are in common use for SC ablation [22]. The ruby laser 
(694 nm) and the alexandrite laser (755 nm) belong to near-infrared (NIR) laser (650 – 
900 nm). The NIR light causes little tissue absorption or minimal thermal effect [23], 
which is not sufficient to remove the SC. By contrast, the wavelengths of the CO2 and 
Er:YAG laser are 10,600 nm and 2,940 nm, respectively. Both lasers directly induce 
heating and microporation of the skin through water excitation and explosive 
evaporation from the epidermis. Between these two laser types, the wavelength of the 
mid-infrared Er:YAG light matches a principal absorption wavelength for water 
molecules [13]. Compared with the CO2 laser, the Er:YAG laser is about 15 times 
better absorbed in skin [22]. Therefore, the Er:YAG laser has a much higher ablation 
efficacy and a lower ablation threshold [24]. The Er:YAG laser shows the reduced 
thermal damage even in deeper crater holes in comparison with the pulsed CO2 laser 
[22, 24]. These favorable properties make the Er:YAG laser an ideal light source not 
only for skin surgery but also for enhanced transdermal drug delivery. A comparison 
of three sources of laser, the ruby, CO2 and Er:YAG laser, on the skin permeability for 
5-Fluorouracil (5-FU) showed that the ruby laser only moderately enhanced the drug 
flux [25]. The Er:YAG laser with fluence at 0.8 – 1.4 J/cm2 enhanced the flux of 5-FU 
 81 
 
by 53 – 133 times than untreated skin. The CO2 laser increased penetration of 5-FU by 
36 – 41 times under the fluences of 4.0 and 7.0 J/cm2 with certain thermal effects [25]. 
Laser-induced thermal ablation heats the skin to hundreds of degrees for very short 
periods of time (micro- to milli-seconds) to disrupt the SC [3]. The extent of structure 
alteration of the SC is proportional to the temperature locally elevated, i.e. (i) 
disordering of SC lipid structure by temperature between 100oC and 150oC, (ii) 
disruption of SC keratin network structure by temperature between 150oC and 250oC, 
and (iii) decomposition and vaporization of keratin to create micron-scale holes in the 
SC by temperature above 300oC [21]. Correspondingly, skin permeability was 
increased from a few fold to three orders of magnitude [21]. For thermal 
ablation-enhanced TDDS, high energy of laser with pulse duration less than 
microseconds is required because it generates limited or negligible heat transfer to 
surrounding tissue [13-16]. The microsecond-pulsed laser steepens the temperature 
gradient across the SC. The skin surface is extremely hot but not the viable epidermis 
and deeper skin tissues [12]. This technique referred to as “cold ablation”, thereby, 
largely eliminates side effects and vastly improves safety.  
In physically enhanced TDDS, the controllable depth and wound area of skin 
perforation by the laser ablation should be well considered. Based on the clinical data 
from microneedle and thermal ablation-enhanced transdermal delivery, micron-scale 
defects in the SC are well tolerated by patients as long as no significant damage to 
living cells in the viable epidermis and dermis [3]. To solve this issue, a laser 
microporation technology called P.L.E.A.S.E.® (Precise Laser Epidermal System; 
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Pantec Biosolutions) has been developed by using a diode-pumped fractional Er:YAG 
laser (Fig. 1A) [14, 15]. Instead of conventional Er:YAG in clinics that ablates a 
7-mm spot on the skin, P.L.E.A.S.E.® generates a matrix of identical micropores with 
100 – 150 µm wide of each (Fig. 1B). Since the concentrated laser beam are divided 
into microbeams, P.L.E.A.S.E.® efficiently and fractionally ablates skin with less 
damages (Fig. 1C) [14]. In addition, the pulse duration of the fractional laser from 
P.L.E.A.S.E.® is shorter than conventional Er:YAG laser to assure the localization of 
heat transfer to the skin surface without allowing heat to propagate to the viable 
tissues below. This technology is patient-friendly since it is programmed to precisely 
control the number of micropores in unit area and depth of micropores based on the 
laser fluence [15].  
3 Photothermal nanoparticle-mediated laser ablation enhancement 
The development of nanotechnology brings a breakthrough to the limited application 
of NIR laser in TDDS. Gold nanostructures such as nanoshells [26], nanorods [27], 
nanocages [28, 29], and hollow nanospheres [30] possess unique optical properties due 
to strong and tunable surface plasmon resonance (SPR). They can be synthesized to 
specifically absorb NIR light and convert photo energy into thermal energy to raise the 
temperature of surrounding tissue [26, 31]. Nanoparticles with the property of 
photothermal coupling effect are called photothermal nanoparticles. Gold 
photothermal nanoparticles can be applied to photothermal ablation therapy of tumor 
cells [32-35], as well as the NIR laser-controlled drug release [36-40]. The absorbance 
of NIR light is desirable because it causes minimal thermal injury to normal tissues 
with optimal light penetration [23, 41]. Recently, a surfactant/protein/gold nanorod 
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complex has been applied to transdermal delivery of proteins [42]. The solid-in-oil 
dispersion system has been formulated through incorporation of gold nanorods as the 
photothermal ablation enhancer to disrupt the skin barrier. This approach effectively 
enhances the protein permeation through the skin in vitro and induces an immune 
response in vivo [42]. In this application, instead of pulsed laser, a xenon lamp that 
required high light power (6 W/cm2) and long duration of light exposure (20 min) has 
been used to ablate the stratum corneum [42]. Therefore, the heat propagation to the 
deeper tissue could be a major concern. 
Semiconductor CuS nanoparticles (CuSNPs) are a new class of photothermal 
nanoparticles that provide an alternative to gold analogs. Compared to gold, CuS is 
much less expensive [43]. Irradiated with NIR laser, CuSNPs generate heat for 
photothermal destruction of tumor cells [43-46]. Hollow CuSNPs (HCuSNPs) have 
been utilized for photothermal ablation-enhanced transdermal drug delivery [47]. A 
nanosecond-pulsed Nd:YAG laser in tandem with Ti:Sapphire laser (900 nm) has been 
used to induce rapid heating of the nanoparticles and instantaneous heat conduction. 
Such type of laser with nanosecond pulse duration provides focused thermal ablation 
of the SC and minimizes skin heat accumulation. The average temperature of the 
irradiated skin area only increases to ~40 – 50oC. The depth of skin perforation can be 
precisely controlled by adjusting the laser power. The skin disruption by 
HCuSNPs-mediated photothermal ablation significantly increases the permeability of 
macromolecule drugs, providing effective percutaneous delivery [47]. 
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4 Drugs applied to laser ablation-enhanced transdermal delivery 
In comparison with chemical enhancers that only improve the transdermal delivery of 
small molecules, laser ablation enhancement makes micrometer dimensions of 
disruptions to the SC structures suitable for the passage of both small and 
macromolecules such as 5-FU [25, 48], lidocaine [14], diclofenac [16], human growth 
hormone (hGH) [47], antithymocyte globulin (ATG) [15], ovalbumin (OVA) [42], 
polypeptides [49], fluorescein isothiocyanate(FITC)-labled dextran (FD) [13], 
nalbuphine [50], vitamin C [51], 5-aminolevulinic acid (ALA) [52], genes [53], and 
stem cells [54] (Table 2).  
Dextran, a hydrophilic macromolecular model drug, was used to evaluate the skin 
permeation. By using a laser with fluence above 1.7 J/cm2, the transdermal transport 
of FDs with molecular weight ranging from 4.4 kDa to 77 kDa was significantly 
enhanced. The possible mechanism could be ablation of the SC layer, 
photomechanical stress on intercellular regions, and alterations of the morphology and 
arrangement of corneocytes by the Er:YAG laser. Further, the transdermal delivery of 
hexameric insulin was higher than that of 38-kDa FD, suggesting the potential of laser 
ablative transdermal delivery of Insulin [13]. 
ATG and Basiliximab, two marketed antibodies for the induction of 
immunosuppression, were studied with fractional Er: YAG laser [15]. The result 
showed that the increase of pore numbers and laser fluence promoted the transdermal 
permeation of the antibodies. Total delivery of ATG at 24 h after laser treatment (900 
pores, at a fluence of 45.3 J/cm2) increased 82.8-fold over the control (untreated skin). 
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Increasing laser fluence from 22.65 to 135.9 J/cm2 enhanced total ATG delivery from 
1.70 ± 0.65 to 8.70 ± 1.55 µg/cm2, respectively. Similar penetration enhancement was 
observed in Basiliximab. Moreover, the in vitro and in vivo result was well correlated 
in a mouse model [15].  
Topical delivery of DNA and RNA were also enhanced by laser ablation [53, 55]. 
With Er:YAG treatment, in vitro permeation of antisense oligonucleotides (ASOs) 
increased  3 – 30-folds, depending on the laser fluence and the molecular weight of 
ASO. In vivo results showed an enhanced expression of plasmid DNA in the epidermis 
and subcutis [53]. Besides, it was also found that the delivery rate of siRNA was 
raised by several times by the laser application [55].  
Laser-enhanced transcutaneous protein delivery provided a non-invasive 
immunization method [15, 56, 57]. The laser induced microporation allowed high 
levels of antigen uptake. Further, transdermal delivery of vaccine targets the potent 
epidermal Langerhans and dermal dendritic cells that generate a strong immune 
response at much lower doses than hypodermic injection [58]. Transcutaneous 
application of OVA via laser-generated micropores using the P.L.E.A.S.E® device 
induced equal or higher immune responses compared to immunization by s.c. injection 
[57]. In addition, targeting different layers of the skin had the potential to bias 
different T cell polarization patterns [57]. The laser ablation enhancement followed by 
transcutaneous immunization of lysozyme with 129 amino acids (14,307 Da) induced 
antigen-specific IgG in the serum by 3-fold compared to the control without laser 
treatment [56].  
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In addition to deliver drug compounds, laser ablation-enhanced transdermal delivery 
of adipose-derived stem cells (ADSC) were explored for wound healings [54]. After 
fractional Er:YAG laser treatment, bromodeoxyuridine (BrdU)-labeled ADSC was 
applied to the laser treated areas. After 4 and 48 hours, 12% and 5.5% of the stem cells 
were found in the pretreated tissue, respectively [54]. This encouraging result 
furthered the studies to optimize the technology for future clinical applications. 
Because of high photothermal conversion effect, the gold nanoparticles were utilized 
to achieve thermal ablation of skin to enhance transdermal delivery of OVA [42]. In 
this study, a solid-in-oil dispersion was formulated to incorporate both the gold 
nanorods and the drug. Therefore, the nanodispersion exerted two modules upon NIR 
light irradiation, i.e. thermal ablation of the SC by the gold nanorods and enhancement 
of skin permeation of OVA. In vivo experiment showed significant increase of 
immune response for the gold nanorod-OVA solid-in-oil dispersion with NIR light 
treatment than other groups [42]. Another study investigated the use of HCuSNPs as 
photothermal ablation enhancers [47]. The permeability of human growth hormone 
(hGH) in skin applied with HCuSNPs plus NIR laser was increased by 3 orders of 
magnitude in comparison with that of the intact skin. In vivo study showed that 
transdermal delivery of hGH using the HCuSNP-mediated photothermal ablation 
technique reached an average bioavailability of 83% relative to that of the 
subcutaneous injection. The peak drug concentration through transdermal delivery was 
only one-third of that via subcutaneous delivery [47]. This was clinical beneficial 
because it reduced the risk of side effect related to high concentrations and controlled 
the drug concentration in a relatively stable level.  
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5 Conclusion 
In conclusion, this review has discussed recent progresses of laser ablation technology 
to enhance transdermal drug delivery. The success of delivery relies on locally thermal 
ablation of the SC. By adjusting the laser fluence and exposure time, the depth of the 
microporation can be controlled without harming the deeper living tissues such as the 
dermis. The microchannels allow skin permeation of hydrophilic and macromolecular 
compounds. Particular interest has been shown in the development of the 
photothermal nanoparticles that mediate photothermal ablation of skin and deliver 
drug in a single setting. As a clean, needle-free and non-invasive approach, laser 
ablation enhancement technology shows great potential for future market. 
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Table 1. Light sources for thermal ablation-enhanced transdermal drug delivery  
Light Source Wavelength  Pulse 
Duration 
Role of the light 
in TDDS 
Other Characteristics 
Traditional Er: 
YAG laser 
2,940 nm 250 – 400 
µs 
Epidermal 
ablation; Dermal 
removal [25, 49]  
One beam; Spot ablation 
Fractional  
Er:YAG laser 
2,940 nm 10 – 300 
µs 
Fractional 
Epidermal 
removal [15] 
Microbeams; Shorter 
pulse; Less damage to 
epidermis; Fractional 
photothermolysis 
Short pulse 
CO2 laser 
10,600 nm 50 ms Epidermal 
removal; Dermal 
thermal injury 
[25] 
Ablation; Vaporization 
Nd:YAG in 
tandem with 
Ti:sapphire 
laser 
690 – 950 
nm 
15 ns Photothermal 
ablation [47] 
Surface plasmon 
resonance by HCuSNPs 
Xenon bulb 750 – 1,000 
nm 
Continuous 
light 
Photothermal 
ablation [42] 
Surface plasmon 
resonance by gold 
nanorods 
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Table 2. Drugs/compounds used for transdermal delivery by laser ablation  
Drug/Compound Indication/Purpose 
Molecule 
Weight 
(Da) 
Enhanced 
Fold of 
Permeability 
Laser 
source 
5-FU Antitumor 130 133 Er:YAG [25, 48] 
Imiquimod Immune response modifier 240.3 127 
Fractional 
Er:YAG 
[49] 
Lidocaine local anesthetic 234.3 13 
Fractional      
Er: YAG 
[14] 
Diclofenac 
Non-steroidal 
anti-inflammatory drug 
(NSAID) 
296.15 118.9 
Fractional      
Er: YAG 
[16] 
Vitamin C Model hydrophilic drug 176 260 Er:YAG [51] 
Methotrexate 
(MTX) 
Psoriasis or rheumatoid 
arthritis  80 
Er:YAG 
[59] 
hGH Growth hormone deficiency 22 k >1000 
Nd: YAG 
tandem 
with Ti: 
sapphire 
[47] 
Antithymocyte/ 
Basiliximab 
Immunosuppressive 
antibodies 
155 k/144 
k 145/ N/A 
Fractional      
Er: YAG 
[15] 
OVA Antigen 44 k ~8 Xenon light [42] 
Beta-galactosidase 
(bGal) Antigen 465 k Significant 
elevation 
Fractional 
Er:YAG 
[57] Recombinant Phl p 5 
grass pollen 
allergen 38 k 
Equine heart 
cytochrome c 
Model proteins 
12.4 k 
From 0 to >0 
Fractional 
Er:YAG 
[60] 
Urinary follicle 
stimulating 
hormone 
30 k 
FITC-labeled 
bovine serum 
albumin 
70 k 
Peptides Model peptides 716 – 2864 10 – 140 
Er:YAG 
[56] 
 
Dextran Model hydrophilic 4.4 k 50 Er:YAG 
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macromolecule 10 – 150 
k From 0 to >0 
[13] 
 Insulin (hexameric) Diabetes mellitus 36 k >100 
Nalbuphine analgesic /Hydrophilic model drug 357 194 Er:YAG 
[50] Indomethacin NSAID/Lipophilic model drug 357 30 
ALA Anti-tumor/photosensitizer 131 260 
Fractional 
Er:YAG 
[52] 
Antisense 
oligonucleotides Test model 5 k – 8 k ~29 
Er:YAG 
[53] 
 Plasmid DNA 
Express green fluorescent 
protein 
4.7 k base 
pairs 160 base pair 
RNA Small interfering RNA 9266 10 Er:YAG [55] 
Adipose-derived 
stem cells wound healing -- 
5.5 – 12 % of 
penetration 
Fractional 
Er:YAG 
[54] 
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Figures 
 
Figure 1. P.L.E.A.S.E® technology. (A), The photograph of the hand-held device. (B), 
Formation of a micropore array in the skin surface using the P.L.E.A.S.E® device. (C), 
Hematoxylin and Eosin staining of micropores created in porcine ear skin after laser 
microporation using the P.L.E.A.S.E® device at fluences of 4.53 J/cm2, 22.65 J/cm2 
or 135.9 J/cm2 (from left to right). From reference.[15] Copyright Elsevier. Reprinted 
with permission. 
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 Cancer is a disease when abnormal cells lose control in the body. It is caused by 
genome damage or the disruption of cellular metabolic processes. It can be inherited 
or induced by external factors. Cancer can form solid tumors on tissues or grow in the 
blood. Solid tumors include cancers of the brain, lung, breast, colon and other tissues.  
 Current first-line treatments include surgery, chemo or radiation therapy. Surgery is 
to remove a cancerous tumor. About 60% of cancer patients undergo surgery. The 
limitation of surgery is that some cancerous cells may not been removed. So it is often 
followed by a combination of other therapy to completely kill all cancer cells. 
Chemotherapy is to use drugs to fight cancerous cells. However, the unselective 
damage of normal cells will also cause significant side effects. Besides, the cancer 
cells can develop drug resistance [1]. Radiation therapy is to use ionizing radiation, 
(X-rays, gamma rays or electrons) to damage the DNA of cancerous cells. It is often 
used to synergize chemotherapy or surgery. However, it can damage healthy tissues 
close to the cancer cells or in the path of the radiation beam. 
 Photothermal therapy (PTT) is a therapeutic method in which electromagnetic 
radiation is converted to heat to treat of various medical conditions including cancer. 
The electromagnetic radiation resources include near infrared or visible light, 
radiofrequency waves and microwaves. They can enhance the temperature in a 
targeting region to destroy the cells[2].   
 PTT possesses a lot of advantages over other therapeutic methods in the treatment 
of cancer. First, in comparison with the most common open surgery for tumor removal, 
photothermal therapy only requires minimal invasion. It can accurately locate the 
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tumor and reduce the harm to health tissue. Therefore, the average hospital stay time 
can be significantly reduced. Second, when compared with commonly applied 
chemotherapy, PTT largely reduces the side effects since it can be guided to focus on 
and ablate the tumor, whereas chemo drugs do not differentiate the normal cells and 
cancer cell. Third, PTT also shows advantages over radiotherapy, which has already 
less the damage to healthy cells due to the precise delivery of high-energy radiation to 
one particular location. Radiation nevertheless presents short-term risks such as skin 
rash or problems with tissues or organs near radiation pass and long-term side effects 
such as infertility or even secondary cancer due to radiation exposure. 
 The heat generated by laser has been used frequently in clinic practice. For example, 
in dentistry, laser is used for photobiomodulation in treatment of recurrent aphthous 
stomatitis and traumatic ulcers to accelerate healing process [3]. It is also used in 
thermal therapy to heat malignant tissue and tumor. Other examples include laser 
coagulation to seal blood vessels and stop bleeding, laser welding to join tissues and 
blood vessels, laser shock waves to remove urinary, kidney and biliary stones [4].  
 The detailed strategy and outcome of PTT on tumor treatment is largely depending 
on the properties of tumor, such as location, size, surface characteristic, water content, 
etc. Generally, laser can only reach less than a few (3–4) centimeters under skin [5]. 
For superficial tumors, external heating could be achieved by superficial applicators. 
For tumors deep inside the body but not close to a body cavity, a fiber need be inserted 
into the center of the target tumor [6]. Moreover, it is important to keep well-localized 
heating high enough in the tumor but not harm the surrounding normal tissue. To 
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achieve this, additional use of real time imaging techniques such as MRI and 
ultrasound imaging are required. 
 PTT has been applied to various solid tumors, including penile cancer, bladder 
tumors, renal tumor, melanoma, cervical cancer, breast cancer and so on. For selected 
cases of penile primary cancer in early stage, Nd:YAG or CO2 lasers therapy was 
found effective [7,8]. For bladder and renal cancer, lasers is feasible for resection, 
coagulation, and enucleation of non-muscle invasive bladder tumors, but it should 
only be used in clinical trial setting or for patients who are not applicable to 
conventional treatment either because of co-morbidities or other complications [9]. 
For cutaneous melanoma, multiple small (<1 cm) lesions respond well to the CO2 laser. 
CO2 laser is recommended or palliative treatment of locoregional recurrence in a limb 
[10]. Local laser ablation can also be used on precancerous dysplasia to prevent 
cervical cancers [11]. 
 There are also a lot of clinical trials for PTT on various carcinomas. For brain 
tumors, patients with recurrence of glioblastoma who had previous received total 
resection, chemotherapy and radiation therapy and ineligible for a secondary surgery 
was proposed for MIR guided laser-induced thermal therapy (LITT) salvage therapy 
[12]. Patients with resistant metastatic intracranial tumors who had previously 
undergone chemotherapy, whole-brain radiation therapy, and radiosurgery were given 
real-time magnetic resonance-guided laser-induced thermal therapy. The procedure 
was safely carried out with minimal invasion in one day [13]. Other MRI-guided laser 
interstitial thermal therapy was investigated on liver metastasis and prostate cancer 
[14–16]. A minimal invasion method, percutaneous laser ablation, by inserting optical 
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fibers into the cancer through 21-gauge needles, is safe and effective for cirrhotic 
patients with hepatocellular carcinoma when resection or liver transplantation is not 
possible [17]. In addition, tumor caused thrombus and mucostis are also eligible for 
laser therapy [18,19]. 
 Normally, tumor larger than 3 cm is not proper for laser ablation. However, a drug 
might change this situation. Sorafenib, a multikinase inhibitor to reduce intratumoral 
blood flow, might enhance the effectiveness of laser ablation on hepatocellular 
carcinoma larger than 4 cm by decreasing cancer microvessel density and thus enlarge 
laser-induced coagulation necrosis area [20]. 
 Recently PTT has attracted new interest because of the arising of photothermal 
nanoparticles, especially gold colloidal. Gold nanoparticles have superior light 
absorption the excited electrons on the surface can produce strong localized heat thus 
damage the cancer cell. Gold nanoparticles have involved in clinical trials. The first 
example, which has phase II result, is gold nanoparticles with silica-iron oxide shell 
for PTT treatment of atherosclerosis. The gold nanoparticles were integrated in stem 
cells grown on a bioengineered patch. Then the patch was implanted onto the artery 
through the minimally invasive cardiac surgery. Under near-infrared laser irradiation, 
the nanoparticles in the patch can burn the plaque. The dense calcium area, fibrous and 
fibro-fatty tissue with fulminant necrosis significantly decreased due to thermolysis of 
the nanoparticles after 12 months [21]. In addition, Tumor necrosis factor (TNF) – 
bound colloidal gold (Aurimmune®) was under phase I clinical trial. Patients with 
advanced solid organ malignancies or primary and metastatic cancer undergoing 
surgical resection received colloidal gold-bound TNF intravenously 12-78 hours prior 
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to surgery. The antitumor effect and biodistribution is still under evaluation [22,23]. 
Another gold nanoparticle based laser photothermal therapy (Aurolase®) is also under 
clinical trial for patients with refractory and/or recurrent tumors of the head and neck 
and subjects with primary and/or metastatic lung tumors. The gold-silica (Auroshell®) 
nanoparticles accumulated at the tumor respond to the interstitial illuminations of an 
808-nm laser [24,25]. 
  Besides gold nanoparticles, other types of nanoparticles are also widely explored. 
For example, graphene, two-dimensional (2D) crystal of sp2-hybridized carbon atom 
arranged in six-membered rings with high optical absorption in the NIR region are 
utilized for PTT to ablating tumor [26,27]. Semiconductor nanocrystals such as CdS, 
CdSe, CdTe, have been intensively used for fluorescence bioimaging due to the size 
and shape-dependent quantum confinement effect [28]. They can efficiently emit 
fluorescence when excited by visible or infrared light. Among those nanostructures, 
some of them were highlighted as photothermal agents due to the high converting 
efficiency of heat. Typical examples include nanostructures of MoS2, CuS, CuSe, 
CuTe, etc [29,30]. Inorganic nanoparticles is hard to degrade in vivo and might 
possess potential long- term toxicity. As a promising substitute, organic nanostructures 
are explored for photothermal therapy based on the discovery of NIR-absorbing 
organic nanomaterials. For instance, indocyanine green (ICG) has been approved by 
FDA. Other NIR dyes include heptamethine indocyanine dye- IR780, IR783, IR808, 
IR825, PcBu4, porphyrins [31–36]. In order to prepare more stable formulation with 
various sophisticated purpose, the NIR dyes incorporated into micelles, liposomes or 
even proteins, have been used for photothermal tumor ablation [37–39]. Conjugated 
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polymers such as polyaniline, polypyrrole and PEDOT: PSS-PEG with extended 
π-electrons also show high NIR absorbance as PTT agents, and have been found to be 
robust photothermal agents [40–42]. In addition, metallic nanoparticles, mesoporous 
silica nanoparticles and rare earth doped nanoparticles were also explored for 
photothermal therapy of cancer [43,44]. It is not possible to highlight just one 
nanoparticle since their parameters are so different. However, they should meet the 
general requirement for in vivo application—deep tissue penetration ability for the 
corresponding wavelength, significant photothermal conversion efficiency and decent 
biocompatibility.  
 PTT is effective for recurrent tumors not sensitive to chemo drug or radiation. 
However, PTT may not be effective against all — particularly cancers that have 
already metastasized all over the body. Chemo drugs, in contrast, are able to distribute 
throughout the body to destroy cancer cells that have spread, although chemo drugs 
might cause huge side effects. The combination of PTT and chemotherapy might 
conquer the limitation of PTT and chemotherapy. Doxorubicin (DOX) is a chemo drug 
used for various cancers, such as blood cancers, many solid tumors and soft tissue 
sarcomas. It works by intercalating DNA and increasing free radical. DOX has a 
‘lifetime maximum dose’ due to its life-threatening dosage-dependent cardiac toxicity 
[45]. In addition to DOX, other chemo drugs were tested for synergistic enhanced 
phothermal therapy effect. For instance, small molecule chemo drugs like 
camptothecin, a DNA enzyme topoisomerase I inhibitor, was loaded into hollow 
copper sulfide nanoparticles for synergistic PTT therapy of cancer cells in vivo [46]. 
Hydrophobic curcumin (regulation multiple cell signaling pathways of tumor cells) 
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was combined in Ag/Au nanogels for PTT [47]. Rotenone, a mitochondrial complex I 
inhibitor, [48] and cisplatin (binding to and causing crosslinking of DNA) and so far 
were also explored [49]. Besides, oligodeoxynucleotides containing cytosine-guanine 
(CpG) motifs (a small single strand DNA functions as immunoadjuvant), single and 
double strand DNA [50], tumor necrosis factor (TNF), antibody anti-VEGFR2, etc 
were all investigated [51]. 
  The CuS nanoparticles are considered as potent counterpart to gold nanoparticles, 
since they are economically efficient, not affected by the surrounding (The PTT of 
CuS nanoparticles originated from d-d* electron transition instead of surface plasmon 
resonance effect), low long-term toxicity [52]. Various Cu2-xS nano composites (e.g. 
chelator-free [(64)Cu]CuS nanoparticles, hollow nanoshell, core-shell nanoparticle 
[46,53,54] have been extensively explored as a transformer of laser to thermal heat 
either accountable for therapeutic effects or as vehicles for drug delivery.  
 Table 1 shows several representative examples of CuS nanoparticles in PTT therapy. 
They are still undergoing bench-side research. However, they are very promising for 
the clinical application. As shown in the table, some CuS structures are used for 
synergistic chemo or immune therapy. Some of them possess very high (56.7%) 
photothermal conversion efficiency. Most of them were tested in animal models with 
subcutaneous inoculation of tumor cells. These mouse xenograft models are 
convenient for intratumoral injection of nanoparticles and laser irradiation spot 
location.  
 In my work, doxorubicin was selected as a model drug and hollow CuS 
nanoparticle and oleylamine-coated CuS were selected as photothermal sensitizers. 
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Doxorubicin utilized could easily form complex with copper through hydrogen bond 
to load DOX. Due to the synergistic effect of photothermal therapy, only a small 
amount of DOX is required, thus the risk of causing heart disease is expected to be 
significantly decreased. The CuS nanoparticles synthesized exhibit remarkable 
photothermal effect. Specifically, hollow CuS NPs have large surface volume and 
considerable number of mesoporous pores beneficial for the drug loading. Unlike gold 
nanostructures such as gold nanorods, they are photo-stable and more biocompatible. 
Oleylamine stabilized CuS are readily dispersible in chloroform without aggregation 
and have facile preparation method.  
 In conclusion, among various photothermal nanoparticles, CuS nanoparticles are 
promising photothermal sensitizers in cancer PTT therapy low toxicity, low cost, high 
efficiency. CuS nanoparticles have great potential for clinical application as gold 
analogs.   
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Table 1. Selective publications on in vivo CuS nanoparticles cancer photothermal 
therapy  
Nanoparticle 
Structure Drug Animal model 
Administrati
on Route 
Laser 
Administrat
ion 
CuS -- -- -- λ = 808 nm [55] 
Cysteine-coated CuS 
nanoparticles -- 
Severe-combined 
immunodeficient 
mice (SCID) bearing 
s.c. xenografts of 
K7M2 osteosarcoma 
cells 
Intratumoral 
injections 
λ = 980 nm  
0.72 W cm−2 
10 min [56] 
Hydrophilic 
flower-like CuS 
superstructures 
-- 
SCID bearing mice 
s.c. xenografts of 
PC-3 human prostate 
cancer cells 
Intratumoral 
injections 
λ = 980 nm  
0.51 W cm−2 
5 min[57] 
Folate 
receptor-targeted 
CuS (FA-CuS) NP 
-- 
Nude mice bearing 
s.c. folate 
receptor-positive KB 
cancer cells 
i.v. injection 
λ = 808 nm 
1.5 W cm−2  
3 min [58] 
Chelator-free 
[64Cu]CuS 
nanoparticles (NPs) 
-- 
Nude mice inoculated 
s.c. with U87 human 
primary 
glioblastomacells 
Intratumoral 
injections 
λ = 808 nm 
16 W cm−2 
5 min [53] 
Hollow CuS 
nanoparticles  Camptothecin  
Kunming mice 
inoculated with H22 
mouse hepatocellular 
carcinoma cells on 
the mammary fat 
pads.  
i.v. injection 
λ = 980 nm 
0.7 W cm−2 
5 min [46] 
Chitosan-coated 
hollow copper 
sulfide nanoparticles 
Oligodeoxynucle
otides containing 
cytosine-guanine 
EMT6 murine mam- 
mary carcinoma 
-bearing mice 
Intratumoral 
injections 
λ = 900 nm 
2.0 W cm−2 
40 s [59] 
Cu9S5@mSiO2 core-Shell 
nanocomposites 
Doxorubicin 
Nude mice of HCT 
116 human colon 
carcinoma model. 
Intratumoral 
injections 
λ = 980 nm 
0.72 W cm−2 
10 min [60] 
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CuS 
nanoparticles-decora
ted graphene oxide 
functionalized with 
polyethylene glycol 
Doxorubicin 
Nude mice bearing 
Hela cervical cancer 
cells 
Intratumoral 
injections 
λ = 980 nm 
1 W cm−2 
5 min [61] 
Cu7S4 Hollow 
Structure -- 
SCID mice 
inoculated s.c. with 
hepatocarcinoma cell 
lines Hep3B cell 
Intratumoral 
injections 
λ = 980 nm 
0.72 W cm−2 
10 min [62] 
CuS NPs stabilized 
with drug-conjugated 
gelatin 
Doxrubicin -- -- 
λ = 808 nm 
6 W cm−2 
10 min [63] 
CuS self-assembly 
Shuttle-like bundles -- -- -- [64] 
Cu7.2S4 nanocrystals  
SCID bearing s.c. 
xenografts of K7M2 
osteosarcoma cells 
Intratumoral 
injections 
λ = 980 nm 
0.72 W cm−2  
7 min [65] 
Gadolinium chelate 
functionalized CuS 
NPs  
-- -- -- 
λ = 808 nm 
6 W cm－2) 
5 min [66] 
Fe3O4@Cu2−xS 
Core−Shell 
Nanoparticles 
-- 
Nude mice bearing 
Hela cervical cancer 
cells 
Intratumoral 
injections 
λ = 980 nm 
0.6 W cm−2 
10 min [55] 
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